Curriculum vitae

Date Updated: January 12, 2023

Name: **Rajal B. Shah, MD**
Dr. Charles T. Ashworth Professor of Pathology

Office Address: UT Southwestern Medical Center
Clements University Hospital
6201 Harry Hines Blvd.
Dallas, TX 75235
Room: UH04.449

Work Phone: **214-633-6364**

Work E-Mail: Rajal.Shah@UTSouthwestern.edu

Education

Year	Degree (Honors)	Field of Study	Institution
1983		High School Diploma	C.N. High School, Ahmedabad, Gujarat, India
1988	MBBS	Medicine	B.J. Medical College, Gujarat University, Gujarat, India

Postdoctoral Training

Year(s)	Titles	Specialty/Discipline	Institution
1989	Clinical Internship	Medicine	Accredited Gujarat University Affiliated Hospitals, Gujarat, India
1994	Resident	Pathology & Microbiology	Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
1999	Resident Physician	Anatomic and Clinical Pathology	St. John Hospital and Medical Center, Detroit, MI
2001	Fellow	Genitourinary & Surgical Pathology	University of Michigan, Ann Arbor, MI

Current Licensure and Certification

Licensure

Name of Board: USMLE Step I, USMLE Step II
Date of Certificate: 09/1993

Name of Board: ECFMG Certification
Date of Certificate: 09/1993

Name of Board: USMLE Step III
Date of Certificate: 05/1999

Name of Board: Diplomat (Board certification) of The American Board of Pathology in combined Anatomic and Clinical Pathology
Date of Certificate: 11/1999

Name of Board: Medical Licensure
Licensure State/Number: Texas / N4738
Date Issued: 11/06/2009

Honors and Awards

Year	Name of Honor/Award	Awarding Organization
1992	1st position, M.D. Pathology & Bacteriology	Gujarat University
1999	Resident research presentation award	St. John Hospital and Medical Center, Detroit, MI
2000	Fellow	College of American Pathologists
2005	Co-chair, Proffered Papers: Genitourinary Pathology	United States and Canadian Academy of Pathology, San Antonio, Texas
2006	Who's Who in Medicine and Healthcare	Marquis
2006	Short course faculty	United States and Canadian Academy of Pathology
2006	Urologic Pathology Abstract Review Board ,	United States and Canadian Academy of Pathology National Meeting Program
2007	Cover article, senior author	Urology journal
2007	Judge	American Journal of Clinical Pathology Resident Research Symposium Competition, New Orleans, LA
2007	America's Top Physician	Consumer Research Council of America
2007	Inaugural American Association of Cancer Research (AACR) team science award for prostate cancer gene fusion work ("In recognition of the landmark discovery of recurrent gene fusions in a majority of prostate cancers, which has profound clinical and biological implications for understanding prostate cancers, and their embodiment of team science through	American Association of Cancer Research

	interdisciplinary and inter-institutional collaboration"),	
2007	Urologic Pathology Abstract Review Board	United States and Canadian Academy of Pathology Annual Meeting Program
2007	Short course faculty	United States and Canadian Academy of Pathology
2008	Cover article, senior author	Histopathology
2008	Who's Who in World	Marquis
2008	America's Top Physician	Consumer Research Council of America
2008	Cover article, Co-senior author	Cancer Research
2008	Short course faculty	United States and Canadian Academy of Pathology
2009	Faculty	College of American Pathologist (CAP) Annual Meeting
2009	Annual Diagnostic Pathology Update Course Faculty	United States and Canadian Academy of Pathology
2009	Co-chair, Proffered Papers Genitourinary Pathology	United States and Canadian Academy of Pathology, Boston, MA
2010	Annual Diagnostic Pathology Update Course Faculty	United States and Canadian Academy of Pathology
2010	Co-chair, Proffered Papers	Genitourinary Pathology: United States and Canadian Academy of Pathology, Washington DC
2010	Cover article, senior author	Human Pathology
2011	Urologic Pathology Abstract Review Board (2nd 4-Year term)	United States and Canadian Academy of Pathology National Meeting Program
2012	Lead Subject Matter Expert	CAP Advanced Practical Pathology Program in the prostate (AP3), Histologic variants, other carcinomas, and non-epithelial lesions of prostate
2013	Excellence in service award	The Association of Indian Pathologists in North America (AIPNA)
2014	Short course faculty for a 3-year term	United States and Canadian Academy of Pathology
2014	Co-moderator, New Frontiers in Pathology	AIPNA-International Academy of Pathology (IAP), Bangkok, Thailand
2014	Co-moderator, Pitfalls in GU pathology: The case that taught me a lesson	International Society of Urologic Pathologists – International Academy of Pathology, Bangkok, Thailand
2016	Expert panel member	CAP reporting protocols for GU organ system
2017	Faculty	CAP
2018	Co-chair, Proffered Papers Genitourinary Pathology	United States and Canadian Academy of Pathology, Vancouver, Canada
2019	Dr. Charles T Ashworth professorship in pathology	University of Texas Southwestern Medical Center, Dallas, Texas
2021	President-Elect	Genitourinary Pathology Society (GUPS)

Faculty Academic Appointments

Year(s)	Academic Title	Department	Academic Institution
11/1/2019-	Professor of Pathology	Pathology	UT Southwestern Medical Center, Dallas, TX
02/2017 – 10/2018	Clinical Associate Professor of Pathology	Pathology	Baylor College of Medicine, Houston, TX
09/2007 – 12/2009	Associate Professor of Pathology	Pathology	University of Michigan, Ann Arbor, MI
09/2007 – 12/2009	Associate Professor of Urology	Pathology	University of Michigan, Ann Arbor, MI
07/2004 – 10/2006	Director and Principal Investigator (PI), Tissue Core, Specialized Program of Research Excellence in Prostate Cancer (SPORE), NIH-Funded Program	Pathology	University of Michigan, Ann Arbor, MI
07/2001 – 08/2007	Assistant Professor of Pathology	Pathology	University of Michigan Hospitals, Ann Arbor, MI
07/2001 – 08/2007	Assistant Professor of Urology	Urology	University of Michigan Hospitals, Ann Arbor, MI
07/1993 – 05/1995	Lecturer	Department of Pathology	Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

Appointments at Hospitals/Affiliated Institutions

Past

Year(s)	Position Title	Department/Division	Institution
10/2018 -10/2019	Staff Pathologist	Department of Pathology	Cleveland Clinic
04/2017 -08/2018	Laboratory Medical Director	Urology	Baton Rouge Urology, Baton Rouge, LA
01/2010 – 10/2014	Medical Director	Urologic Pathology	Inform Diagnostics (Previously Miraca Life Sciences), Dallas, TX
07/2002 – 12/2009	Director, Urologic Pathology Fellowship	Anatomic Pathology, Department of Pathology	University of Michigan
11/2006 – 12/2009	Co-Director, Tissue Core	Michigan Specialized Program of Research Excellence in Prostate Cancer (SPORE), NIH-Funded Program	University of Michigan
07/2004 – 10/2006	Director, Tissue Core	Michigan Specialized Program of Research Excellence in Prostate Cancer (SPORE), NIH-Funded Program	University of Michigan

Current

Year(s)	Position Title	Department/Division	Institution
11/2019-	Staff pathologist	Department Pathology	Clements University Hospital, Dallas, Texas
11/2019-	Staff pathologist	Department Pathology	Parkland Hospital, Dallas, Texas
07/2022-	Fellowship director, Genitourinary selective pathology	ACGME certified program, department of pathology	UT Southwestern Medical Center, Dallas, Texas

Major administrative/Leadership Positions

Year(s)	Position Title	Institution
03/2019-10/2019	Director	Genitourinary Pathology, Cleveland Clinic
10/2014- 10/2018	Vice President, Medical Director	Urologic Pathology Inform Diagnostics, Dallas, TX (Previously known as Miraca Life Sciences)
10/2004 –12/2009	Section Chief, Urologic Pathology	Anatomic Pathology, University of Michigan

Committee Service

Year(s)	Name of Committee	Institution/Organization
National/International		
2001 – 2007; 2011 – 2019	Treasurer and Secretary	Association of Indian Pathologists in North America
03/2019 – Present	Secretary	Genitourinary Pathology Society(GUPS)
03/2019 – 03/2021	Chair, Membership, and Diversity Committee	Genitourinary Pathology Society (GUPS)
03/2021-	President-Elect	Genitourinary Pathology Society (GUPS)
10/2021-	Education committee member	Genitourinary Pathology Society (GUPS)
10/2021-	Education committee member	Texas Society of Pathology

Professional Societies

Dates	Society Name, member
1996 – Present:	College of American Pathologists
1997 – Present:	American Society of Clinical Pathologist
1998 – Present:	United States and Canadian Academy of Pathology
2001 – Present:	International Society of Urologic Pathology
2002 – Present:	American Urological Association, Inc.
2019 – Present:	Genitourinary Pathology Society

Editorial Activities

Year(s)	Journal Name
Editorial Board	
2020	Co-chief Editor, Path Presenter, High yield urologic pathology digital slide collection
2014	Human Pathology
2005	International Board of Advisers: Indian Journal of Pathology and Bacteriology (IJPM)
2014	Gujarat Journal of Pathology and Microbiology
Ad Hoc Reviewer	
	American Journal of Surgical Pathology
	Archives of Pathology and Laboratory Medicine
	BMC Cancer
	Cancer

	Cancer Research
	Clinical Cancer Research
	Journal of Clinical Pathology
	Journal of Histochemistry and Cytochemistry
	Journal of Urology
	Laboratory Investigation
	Modern Pathology

Grant Support

Present	None

Past	***Grantor:***
2018	Co-Principal Investigator, Central Pathology Reviewer, Progenics, Phase III clinical trial evaluating the feasibility of imaging modality to determine clinically insignificant prostate cancer. (Ongoing extramural funded research), Ended 06/2018
07/2003-05/2008	University of Michigan Prostate SPORE (Specialized Program for Research Excellence), $251,033 – Co-Principal Investigator, Tissue and Serum Core Resource Grant -NIH- P50 CA69568 (Pienta)-07/01/2003-05/31/2008 - 2.4 calendar Inter prostate biomarker study (IPBS) – Principal Investigator, University of Michigan, (NIH funded pilot of biomarker validation) 0% salary support
03/2005-03/2008	Molecular profiling of prostate cancer, Co-investigator, W81XWH-05-1-0173 (PI-A. Chinnaiyan), $61,858 – 03/07/2005-03/06/2008 - 0.3 calendar
07/2003-05/2008	Evaluation & Development of Non-peptide MDM2 inhibitors in the treatment of metastatic prostate cancer. Co-investigator, P50 CA069568 (PI-Pienta/Shaomeng Wang), $150,000 – 07/01/2003-05/31/2008 - 0.6 calendar.
07/2003-05/2008	Prostate Cancer Imaging for Radiation. Co-investigator, P50 CA069568 (PI-Piert), $40,286-2% salary support, 07/01/2003-05/31/2008 - 0.24 calendar.
07/2001-06/2004	Role of the Human Polyomavirus, BKV, in Prostate Cancer - Co-investigator, Department of Defense/ USAMRMC, DAMD17-01-1-0076 (M.J. Imperiale) - 7/1/2001-6/30/2004 - 5% salary support
	ErbB Signaling in Prostate Cancer Progression - Co Investigator, DRDA 1234, UMCC 1234; CRC 1234E
04/2001-03/2005	Analysis of 8P loss in Human Prostate Cancer – Co-Investigator, RO1, 5RO1 CA 60948-08, (J.A. Macoska, PI), 4/01/2001 to 3/31/2005 - 5% salary support.

Teaching Activities

Year(s)	**Activity**
Medical and graduate school didactic and small group teaching	
July 2001 – December 2009,	University of Michigan, Ann Arbor, MI
	1. Pathology Residents – Three didactic lectures, consult conferences, regular surgical pathology, and urological pathology sign-outs/year.

	2. Urology Residents - monthly conferences.
	3. MS2 Medical Students - renal and reproductive sequence lectures.
October 2018 – October 2019	Cleveland Clinic, Cleveland, OH
	Pathology Residents – Regular genitourinary pathology sign-out service, 1 didactic conference, and 1 multi-head interactive microscopy session
	Genitourinary Pathology Fellow – Regular genitourinary pathology sign-out service
November 2019-present	Clements University Hospital, UT Southwestern Medical Center
	Pathology Residents – Regular genitourinary pathology sign-out service, 1 didactic conference, and 1 multi-head interactive microscopy session
	Genitourinary Pathology Fellow – Regular genitourinary pathology sign-out service
2020-	**YouTube Channel: "Rajal B. Shah, MD. Expert Urologic Pathology" Over 37 videos, over 3.4 K subscribers, 96000 views**

Post Graduate student trainees

07/2002 -06/2003	Lakshmi P. Kunju, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
07/2003 -06/2004	Matthew Snyder, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
07/2004 -06/2005	Nasir Bakshi, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
07/2007 -06/2008	Angela Wu, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
07/2008 -06/2009	Mathew Wasco, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
07/2009 -12/2009	Jason Carvalho, M.D., Genitourinary Pathology Fellowship, University of Michigan, Ann Arbor, MI
11/2019-06/2020	Sasan Setadooh, MD, Genitourinary Pathology Fellowship, UT Southwestern Medical Center, Dallas, TX
07/2020-06/2021	Christopher Matter, MD, Genitourinary Pathology Fellowship, UT Southwestern Medical Center, Dallas, TX
07/2021-06/2022	David Kim, Genitourinary Pathology Fellowship, UT Southwestern Medical Center, Dallas, TX
07/2022-	Jing Sun, Genitourinary Pathology Fellowship, UT Southwestern Medical Center, Dallas, TX

Course director/co-director of national-level continuing medical education activities

2005	Select Diagnostic Difficulties in Urologic Pathology" – case presentations and review. – Visiting Lecturer, Cleveland Clinic Foundation, November 11, 2005.
2005	Interpretation of Prostate Needle biopsies. Case presentations and review."- 23rd MLABS symposium April 9, 2005.
2006	Interpretation of Prostate Needle Biopsies: Critical Issues and Emerging Markers". – Short course, course director, United States and Canadian Academy of Pathology, Atlanta, GA. February 15, 2006 (for a 4-year term).
2006	Contemporary Issues in Prostate, Urinary Bladder and Renal Pathology" – Weekends in Pathology, American Society of Clinical Pathologists (ASCP): Las Vegas, February 26, 2006
2007	Interpretation of Prostate Needle Biopsies: Critical Issues and Emerging Markers" – Short course, course director, United States and Canadian Academy of Pathology, San Diego, CA, March 30, 2007.
2007	Contemporary Issues in Prostate, Urinary Bladder, and Renal Pathology" – American Society of Clinical Pathologists (ASCP) annual meeting: New Orleans, LA, October 18, 2007

2007	Select diagnostic difficulties and contemporary issues in Urologic Pathology" – Video Microscopy tutorial, American Society of Clinical Pathologist (ASCP) annual meeting, New Orleans, LA, October 19, 2007
2008	Contemporary Issues in Prostate, Urinary Bladder, and Renal Pathology" – Weekends in Pathology, American Society of Clinical Pathologists (ASCP): Chicago, June 21, 2008.
2009	Interpretation of Prostate Needle Biopsies: Critical Issues and Emerging Markers" – Short course, course director, United States and Canadian Academy of Pathology, Boston, Massachusetts, March 2009
2009	Interpretation of Prostate Needle Biopsies: Critical Issues and Emerging Markers" – USCAP Practical Pathology Seminars, San Francisco, CA, May 2009
2009	United States and Canadian Academy of Pathology - Diagnostic Pathology Update Course, GU section, Niagara Falls, Canada, July 2009
2009	Contemporary issues and emerging concepts in prostate needle biopsy interpretation and reporting: diagnosis and differential diagnosis, Gleason grading and more"- College of American Pathologists Annual Meeting, Washington D.C., October 2009
2010	Contemporary Issues in Urologic Pathology" – Weekends in Pathology, American Society of Clinical Pathology Meeting, Las Vegas, Nevada, February 2010.
2010	United States and Canadian Academy of Pathology - Diagnostic Pathology Update Course, GU section, Lake Tahoe, Nevada, USA, July 2010.
2010	Contemporary issues and emerging concepts in prostate needle biopsy interpretation and reporting: diagnosis and differential diagnosis, Gleason grading and more"- College of American Pathologists Annual Meeting, Chicago, September 2010
2010	AIPNA - ASCP: Frontiers In Diagnostic Urologic Pathology: Wednesday, October 27, 2010, American Society of Clinical Pathology National meeting, San Francisco, CA, October 2010.
2011	Contemporary issues and emerging concepts in prostate needle biopsy interpretation and reporting: diagnosis and differential diagnosis, Gleason grading and more"- College of American Pathologists Annual Meeting, Grapevine, Texas, September 2011.
2013	Interpretation of Prostate needle biopsies: Contemporary issues and emerging concepts" – American Society of Clinical Pathology, Annual Meeting, Las Vegas, NV, October 2011
2014	High yield urological pathology: common and important diagnoses not to be missed in daily practice" – American Society of Clinical Pathology, Annual Meeting, Chicago, IL, September 2013.
2014	High yield urological pathology: common and important diagnoses not to be missed in daily practice" – Short course, United States and Canadian Academy of Pathology, Annual Meeting, San Diego, CA, February 2014.
2015	High yield urological pathology: common and important diagnoses not to be missed in daily practice" – Short course, United States and Canadian Academy of Pathology, Annual Meeting, Boston, MA, March 2015.
2016	High yield urological pathology: common and important diagnoses not to be missed in daily practice" – Short course, United States and Canadian Academy of Pathology, Annual Meeting, Seattle, WA, March 2016.
2016	Recognizing Morphologic Variations of Prostate Carcinomas, Other Carcinomas, and Nonepithelial Lesions". The online 2.50 CME/SAM module, CAP AP3 program, 2016
2017	"New Things" in 2016 WHO Tumors of Urinary System and Male Genital Organs Blue Book and 8th Edition of AJCC Staging that Every Pathologist Should Know, CAP Annual Meeting, Washington, DC, October 2017.
2019	"New Things" in 2016 WHO Tumors of Urinary System and Male Genital Organs Blue Book and 8th Edition of AJCC Staging that Every Pathologist Should Know, CAP Annual meeting, Gaylord Palms Resort and Convention Center, Orlando, FL, September 24, 2019
2020	New concepts in urologic pathology. Prostate cancer with "cribriform architecture" (intraductal carcinoma and invasive Gleason pattern 4), American Society of Clinical Pathology, Virtual Meeting, September 2020
2021	PathPresenter Masterclass in Pathology: Diagnostic approach to prostate cribriform lesions

2022	The 2022 Classification of GU Tumors: Don't Let the New Blue Book Make You Blue, Interactive microscopy course, USCAP, Palm Springs, November 15-17
Postdoctoral trainees	
07/2003 -06/2006	Rohit Mehra, M.D., Postdoc Molecular Pathology Fellow (Co-Mentorship with Arul Chinnaiyan, M.D., Ph.D.)

Invited Lectures

Year(s)	Title	Location
International		
2000	Practical applications of Flow Cytometry in the immunophenotypic analysis of Leukemia's and Lymphomas.	December 2000, Guest Speaker, Association of Pathologists, Gujarat Chapter, Ahmedabad, India.
2005	Contemporary Classification of Renal Epithelial Neoplasms: critical issues.	Guest speaker, Association of Pathologist and Microbiologist, Gujarat chapter, Ahmedabad, India, December 20, 2005
2008	"*TMPRSS2-ETS*" Family Gene Rearrangements in Prostate Cancers. – Guest Speaker, Convention for Human Medical Genetics, Foundation for Research in Genetics and Endocrinology.	Institute of Human Genetics, January 6, 2008, Ahmedabad, Gujarat, India
2008	Recent advances in prostate cancer biomarkers – recurrent fusions of *TMPRSS2-ETS* family Genes	NHL municipal medical school and VS Hospital, Association of Pathologists and Microbiologist, Gujarat chapter, January 11, 2008, Ahmedabad, Gujarat, India
2009	The discovery of common recurrent *TMPRSS2:ETS* gene fusions in prostate cancer: Significance and clinical implications.	Krishna Institute of Medical Sciences, Moving Academy of Medicine and Biomedicine, and Association of Indian Pathologists in North America, Karad, India, January 31, 2009
2009	Contemporary Issues in Bladder Cancer Diagnosis and Management	All India Association of Pathologist and Microbiologist, XIV Indo-US International CME in Pathology, Hosted by Gwalior Medical College, AIPNA chapter, Agra, India, February 4, 2009
2009	Selected Recent Entities and Contemporary Issues in Renal Neoplasms	All India Association of Pathologists and Microbiologists, XIV Indo-US International CME in Pathology, Hosted by Gwalior Medical College, AIPNA chapter, Agra, India, February 4, 2009.
2009	Contemporary Issues in Bladder Cancer Diagnosis and Management.	Association of Pathologists and Microbiologists, Ahmedabad, India, February 8, 2009
2012	Gleason Grading and its Relevance in Prostate Cancer Management.	Institute of Kidney Diseases and Research Center, Civil Hospital, Ahmedabad, Gujrat, India, February 22, 2012.
2012	Contemporary Issues in Prostate Pathology	CME workshop, BJ Medical College, Ahmedabad, Gujarat, India, February 18, 2012.

2012	Intraductal Carcinoma of the Prostate (IDC-P): Current Concepts, Differential Diagnosis and Role of Common *ERG* Gene Fusions.	International Academy of Pathology Meeting, Cape Town, South Africa, October 4, 2012.
2014	Variant Histological Differentiation in Urothelial Carcinoma: An Update with an Emphasis on Emerging Concepts in Micropapillary Carcinoma. New Frontiers in Pathology, AIPNA-IAP Forum.	International Academy of Pathology meeting, Bangkok, Thailand, October 9, 2014.
2014	"Atypical Cribriform Lesions of the Prostate" In Pitfalls in GU Pathology: the case that taught me a lesson session, ISUP-IAP session.	International Academy of Pathology meeting Bangkok, Thailand, October 9, 2014.
2016	Select Contemporary Issues and Newer Entities in Urologic Pathology.	The 21st AIPNA-ICP International CME, Bhubaneshwar, Odisha, India, January 29, 2016.
2016	Current Concepts on Gleason Grading of Prostate Cancer.	The 21st AIPNA-ICP International CME, Bhubaneshwar, Odisha, India, January 29, 2016.
2018	Bladder Cancer: "New Things" in 2016 WHO classification and 8th edition of AJCC staging.	The 23rd AIPNA-ICP International CME, Navi Mumbai, Maharashtra, India, January 19, 2018.
2018	"New Things" in prostate cancer classification, grading, staging and reporting.	The 23rd AIPNA-ICP International CME, Navi Mumbai, Maharashtra, India, January 19, 2018.
2018	Diagnosis of Limited Prostate Cancer and Atypical Glands Suspicious for Prostate Cancer in Prostate Biopsy.	The XXXII Congress of the International Academy of pathology, King Hussein Bin Talal Convention Center, Dead Sea, Jordan, October 17, 2018.
2020	Diagnosis of prostate cancer on core needle biopsy: A 3-step approach	AIICME 2020, jointly organized by ICP and AIPNA, Ahmedabad, February 1, 2020
2020	Essentials of Gleason grading of prostate cancer: An update	AIICME 2020, jointly organized by ICP and AIPNA, Ahmedabad, February 1, 2020
2021	Contemporary Gleason Grading of Prostate Cancer: An Update	British Association of Urological Pathologists (BAUP), January 7, 2021
2021	Intraductal lesions of prostate: Group Session	British Association of Urological Pathologists (BAUP), January 7 and 8, 2021
2021	Contemporary Gleason Grading of Prostate Cancer: An Update	British Association of Urological Pathologists (BAUP), May 24, 2021
2021	Intraductal lesions of prostate: Group Session	British Association of Urological Pathologists (BAUP), May 24 and 25, 2021
2021	PathPresenter Masterclass in Pathology: Diagnostic approach to prostate cribriform lesions	Organized by PathPresenter, a virtual microscope educational platform, August 13-15, 2021
2021	Histological criteria of prostate cancer	British Association of Urological Pathologists (BAUP), September 13, 2021
2021	Benign mimics of prostate cancer: group session	British Association of Urological Pathologists (BAUP), September 14, 2021
2021	Quiz cases: Presentation of unknown cases	British Association of Urological Pathologists (BAUP), September 14, 2021
2021	Interactive Microscopy Session: Diagnostic approach to cribriform lesions: Select contemporary issues	5d Urogenital Pathology Meeting, Plzen, CZ Republic, October 14, 2021
2021	Renal cell carcinoma with fibromyomatous stroma: A distinct entity or group of lesions?	5d Urogenital Pathology Meeting, Plzen, CZ Republic, October 15, 2021

2021	"The Grey Zones in Classification of Renal Cell Tumors with Clear Cytoplasm"	8th Annual Histopathology Virtual Meet "The Grey Zones-with the Masters" GZM 2021, 25th September 2021, India
2021	Update on Gleason Grading of Prostate cancer	Hot topics in anatomic pathology 2021, Virtual Meeting, Organized by anatomic pathology Association, New Zealand
2022	Atypical large gland proliferation of prostate gland	British Association of Urological Pathologists (BAUP), Leeds, UK, September 29-30, 2022
2022	Cribriform prostate carcinoma: New concepts, challenges, controversies, and differential diagnosis: Group microscopical session	British Association of Urological Pathologists (BAUP), Leeds, UK, September 29-30, 2022
2022	Quiz cases: Presentation of unknown cases	British Association of Urological Pathologists (BAUP), Leeds, UK, September 29-30, 2022
2022	Cribriform and intraductal prostate cancer – current challenges and future perspectives	XXXIV International Congress of the International Academy of Pathology (IAP) 2022 – Virtual Meeting, 11-12 October
2023	Gleason grading of prostate cancer – pearls, pitfalls and controversies	11th January, Gujarat Cancer and Research Institute (GCRI), Ahmedabad, India
2023	Atypical large gland proliferation of prostate gland	British Association of Urological Pathologists (BAUP), January 17, 2022
2023	Cribriform prostate carcinoma: New concepts, challenges, controversies, and differential diagnosis: Group microscopical session	British Association of Urological Pathologists (BAUP), January 18, 2023
2023	Quiz cases: Presentation of unknown cases	British Association of Urological Pathologists (BAUP), January 18, 2023
National		
2004	Prostate SPORE Tissue Core Infrastructure - University of Michigan Experience	The Cleveland Clinic Foundation Delegation, January 15, 2004
2005	Prostate Cancer: From a Pathologist's Perspective	The Prostate Cancer Education and Support Network, The University of Michigan Comprehensive Cancer Center, January 6, 2005.
2005	What is up and what is down in prostate pathology: New frontiers in pathology practices of genitourinary pathology"-Guest speaker, companion meeting.	The American Society of Clinical Pathology (ASCP): Pathology Today meeting, Seattle, WA, October 7, 2005.
2003	Prostate SPORE Tissue Core Infrastructure - University of Michigan Experience.	Israeli Delegation, June 25-26, 2003
2004	Recent changes in the Staging and Classification of Genitourinary Cancers-an update	Genitourinary Oncology Conference, University of Michigan Hospitals, January 15, 2004
2004	Interpretation of Prostatic Pathology: Critical Issues and Emerging Markers.	Association of Pathologists and Microbiologists, Gujarat Chapter, India, January 31, 2004.
2005	Interpretation of Prostate Needle Biopsies: critical issues and emerging markers	Cleveland Clinic Foundation, October 11, 2005

2006	Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro Dissected Prostate Tissues.	The SPORE meeting, Baltimore, July 21, 2006
2006	Immunophenotype of Prostate Cancer: Biomarkers of early detection to end-stage metastatic prostate cancer"	Department of Pathology, Stanford University Hospital, California, October 2, 2006
2006	Select diagnostic difficulties in Urologic Pathology	Department of Pathology, October 2, 2006, Stanford University, California.
2007	Comprehensive assessment of *TMPRSS2* and *ETS* gene fusion assessment in clinically localized prostate cancer"	The 3rd Michigan Urology Symposium, Ann Arbor, MI, June 12, 2007
2007	"*TMPRSS2-ETS* gene rearrangements in clinically localized prostate cancers" – guest lecturer, Department of Pathology.	University of California at Los Angeles, California, August 10, 2007
2008	Urologic Pathology Breakout Session, Part 1: Gleason grading of prostate cancer: New Frontiers in Diagnostic Pathology. An Update for Practicing Pathologists.	University of Michigan Department of Pathology and A. James French Society of Pathologists symposium, September 28, 2008, Ann Arbor, MI.
2008	Urologic Pathology Case Presentation: New Frontiers in Diagnostic Pathology: An Update for Practicing Pathologists.	University of Michigan Department of Pathology and A. James French Society of Pathologist symposium, September 28, 2008, Ann Arbor, MI
2008	Urologic Pathology Breakout Session, Part 3: Interpretation of flat urothelial lesions: New Frontiers in Diagnostic Pathology: An Update for Practicing Pathologists.	University of Michigan Department of Pathology and A. James French Society of Pathologist symposium, September 28, 2008, Ann Arbor, MI
2009	Contemporary Issues in Bladder Cancer Diagnosis and Management.	Flint Society of Pathologists Meeting, Hurley Hospital, Flint, MI, January 14, 2009
2011	Grand Rounds: Cribriform Lesions of Prostate: Diagnosis and Differential Diagnosis, and Emerging Concepts of Intraductal Carcinoma and More.	Memorial Sloan Kettering Cancer Center, NY, NY June 14, 2011.
2011	GU slide seminar: Potpourri of Interesting Urologic Pathology Disease Spectrum Encountered in Outpatient Practice.	Memorial Sloan Kettering Cancer Center, NY, NY, June 15, 2011.
2017	"Interesting GU cases that I encountered in my practice" GU unknown slide case conference.	UCLA, Department of Pathology, Los Angeles, CA. December 11, 2017
2017	"New Things" in prostate cancer classification, grading, staging and reporting, and more.	UCLA, Department of Pathology, Los Angeles, CA. December 11, 2017
2017	GU evening subspecialty case conference	The United States and Canadian Academy of Pathology, March 5, 2017, San Antonio, Texas
2018	Neuroendocrine tumors of the prostate gland	The American Society of Clinical Pathology annual meeting, AIPNA companion meeting session, Baltimore, MD, October 5, 2018.
2019	Hot Topics in Pathology: "Prostate Cancer Pathology, Grading, Reporting, Diagnosis".	Presentation. The United States and Canadian Academy of Pathology meeting, National Harbor, MD, March 20 2019.
2019	"A 3-Step Approach to Prostate Cancer Diagnosis in Core Needle Biopsy".	Presentation, Arizona Society of Pathologists, April 13, 2019.
2019	Update on Prostate Cancer: New Developments in Diagnosis, Grading, Staging, and Reporting".	Presentation, Arizona Society of Pathologists, April 13, 2019.
2019	Update on Bladder Cancer: What is New in 2016 WHO Classification and 8th Edition of AJCC Staging Manual	Presentation, Arizona Society of Pathologists, April 13, 2019

2019	"The diagnosis of prostate cancer on core needle biopsy: A 3 step approach".	Cleveland Clinic, September 30, 2019
2021	Digital pathology and artificial intelligence in genitourinary pathology: present and future perspective	Genitourinary Pathology Society Companion Society Meeting, United States and Canadian Academy of Pathology Meeting, March 2021
2022	Introduction to GUPS-PathPresenter Initiative and moderator	GUPS virtual education series, September 12
Regional/Local		
2011	Common ERG gene fusions in prostate cancer: significance and clinical implications.	GU Journal Club, Caris Life Sciences, Irving, Texas, May 26, 2011
2016	Critical Role of Pathologist in Prostate Cancer Diagnosis and Management.	National Society of Histotechnology, TSH District 1 Sept Meeting. September 10, 2016, Dallas, Texas.
2018	Grand Rounds: Update on Bladder Cancer: What's New in 2016 WHO classification and 8th Edition of AJCC staging Manual	Baylor College of Medicine, Houston, TX, April 30, 2018
2018	"Select Contemporary Issues in Urologic Pathology" an interactive microscopic unknown case conference	Baylor College of Medicine, Houston, TX, April 30, 2018
2019	Select Contemporary Issues in Urologic Pathology" –an interactive unknown case conference.	UT Southwestern Medical Center, Dallas, TX, May 28, 2019
2020	Diagnosis of prostate cancer on core needle biopsy; A 3-step approach	UT Southwestern Medical Center, Dallas, TX, May 6, 2020
2020	Prostate Cancer Grading: Contemporary Issues and Controversies	North Texas Society of Pathology (NTSP), December 17th, 2020
2021	Cribriform Prostate Cancer: An Old Entity With The New Realizations	Texas Society of Pathology, January 30, 2021
2021	Pathologic and Clinical Significance of Prostate Cancer with Cribriform Architecture	2021 Annual Spence Visiting Professor Day, UTSW Urology department, May 24, 2021
2022	Atypical Large Gland Proliferations of the Prostate Gland	Houston Society of Clinical Pathologists, October 19

Bibliography

Peer-Reviewed Publications

Original Research Articles

1.	Patel A, Kothari J, Patel K, Shukla S, **Shah RB**, Anand A, Parikh B, Giri D, Shah P. Retroperitoneal Lymphangioma. Indian Journal of Pediatrics. 1994, 61(2):194-197.
2.	Wang Q, **Shah RB**, McCormic D, Lomo L, Giraldo A, David C, Kong Y. H2E Transgenic Class II-Negative Mice Can Distinguish Self From Nonself in Susceptibility to Heterologous Thyroglobulins in Autoimmune Thyroiditis. Immunogenetics. 1999, 50:22-30.
3.	**Shah R**, Bassily N, Wei J, Mucci NR, Montie J, Sanda M, Rubin MA. Benign Prostatic Glands at Surgical Margins of Radical Prostatectomy Specimens: Frequency and Associated Risk Factors. Urology. 2000, 56: 721-725.
4.	**Shah RB**, Lee M, Giraldo A, Amin M. Histologic and Histochemical Characterization of Seminal Vesicle Intraluminal Secretions: Particular Emphasis on Their Crystalloid Morphology. Arch Pathol Lab Med. 2001, 125:141-145.
5.	**Shah R**, Mucci N, Amin A, Macoska J, Rubin M. Postatrophic Hyperplasia of the Prostate Gland: Neoplastic Precursor or Innocent Bystander? Am J Pathol. 2001, 158:1775-1784.

6.	Dhanasekaran S, Barrette T, Mucci N, **Shah RB**, Kurachi K, Pienta K, Rubin MA, Chinnaiyan AM. Molecular Profiling of Prostate Cancer: Delineation of Candidate Biomarkers and Regulatory Genes. Nature. 2001, 412:822-826.
7.	Zhou M, Hayasaka S, Taylor JM, **Shah R**, Proverbs-Singh T, Manley S, Rubin MA. Lack of Association of Prostate Carcinoma Nuclear Grading with Prostate Specific Antigen Recurrence After Radical Prostatectomy. Journal of Urology. 2001, 166:2193-2197.
8.	Qiang W, **Shah RB**, Panos JC, Giraldo AA, David CS, Kong YC. HLA-DR and HLA-DQ Polymorphism in Human Thyroglobulin-Induced Autoimmune Thyroiditis: DR3 and DQ8 Transgenic Mice are Susceptible. Human Immunology. 2002, 63:301-310.
9.	**Shah RB**, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the Basal Cell-Specific Markers, 34βE12 and p63, in the Diagnosis of Prostate Cancer. Am J Surg Pathol. 2002, 26(9):1161-1168.
10.	Joshi D, **Shah RB**, Montie J, Lee C. Isolated Recurrent Renal Cell Carcinoma Metastatic to the Bladder. JNMA. 2002, 94(10):912-914.
11.	Zhou M, **Shah R**, Shen R, Rubin M. Basal Cell Cocktail (34βE12+p63) Improves the Detection of Prostate Basal Cells. Am J Surg Pathol. 2003, 27(3):365-371.
12.	Kunju LP, Rubin M, Chinnaiyan A, **Shah RB**. Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. Am J Clin Pathol, 120(5):737-745, 2003.
13.	Skitzki J, **Shah RB**, Francis I, Chang A. Hepatic Angiomyolipoma: An Unusual Liver Tumor. Contemporary Surgery. 2003, 59(8):370.
14.	Kumar-Sinha C, **Shah RB**, Laxman B, Tomlins S, Harwood J, Schmitz W, Conzelmann E, Sanda M, Wei J, Rubin M, Chinnaiyan A. Elevated alpha-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer. Am J Pathol. 2004, 164(3): 787-93.
15.	Kalikin L, Schneider A, Thakur M, Fridman Y, Griffin L, Dunn R, Rosol T, **Shah RB**, Rehemtulla A, Pienta M and K. In Vivo Visualization of Metastatic Prostate Cancer and Quantitation of Disease Progression in Immunocompromised Mice. Cancer Biology and Therapy. 2003, 2(6):656-660.
16.	**Shah RB**, Kunju L, Shen R, LeBlanc M, Rubin M. Usefulness of Basal Cell Cocktail (p63+34βE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. Am J Clin Pathol. 2004, 122:517-523.
17.	Das D, **Shah RB**, Imperiale M. Detection and Expression of Human BK Virus Sequences in Neoplastic Prostate Tissues. Oncogene. 2004, 23: 7031-46.
18.	**Shah RB**, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M, MacVicar G, Varambally S, Harwood J, Bismar T, Kim R, Rubin M, Pienta K. Androgen Independent Prostate Cancer is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program. Cancer Research. 2004; 64:9209-9216.
19.	Kunju L, Lee C, Montie J, **Shah RB**. Cytokeratin 20 and Ki- 67 as Markers of Urothelial Dysplasia. Pathol Int. 2005, 55(5):248-54.
20.	Khaira H, **Shah RB**, Wolf S, Jr. Laproscopic and Open Surgical Nephrectomy for Xanthogranulomatous Pyelonephritis. Journal of Endourology. 2005, 19(7):813-17.
21.	Siu W, Dunn RL, **Shah RB**, Wei JT. Use of Extended Pattern Technique for Initial Prostate Biopsy. J Urol. 2005; 174(2):505-9.
22.	Kunju L, Chinnaiyan A, **Shah RB**. Comparison of Utility of Polyclonal and Monoclonal Antibody to alpha Methyl Acyl Co a Racemase (AMACR) in Work-up of Prostate Cancer. Histopathology; 47(6); 587-96, 2005.
23.	Ergen FB, Hussain H, Caoili EM, Korobkin M, Carlos RC, Weadock WJ, Johnson TD, **Shah R**, Hayasaka S, Francis IR. MRI for Preoperative Staging of Renal Cell Carcinoma Using the 1997 TNM Classification with Surgical and Pathologic Staging. AJR. 2004; 182:217-225.
24.	Fu Z, Kitagawa Y, Shen R, **Shah RB**, Mehra R, Rhodes D, Keller P, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. The metastasis suppressor gene Raf Kinase inhibitor (RKIP) is a novel prognostic marker in prostate cancer. The Prostate. 2006, 66:248-256.
25.	Ray M, Wojno K, Goldstein NS, Olson KB, **Shah RB**, Cooney K. Clonality of Sarcomatous and Carcinomatous Elements in Sarcomatoid Adenocarcinoma of the Prostate. Urology. 2006, 67:423e5-423e8.
26.	Caoili EM, Cohan RH, Inampudi P, Ellis JH, **Shah RB**, Faerber GJ, Montie JE. MDCT Urography of Upper Tract Urothelial Neoplasms. AJR. 2005;184:1873-1881.
27.	Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sooryanarayana V, Cao X, Kuefer R, Lee C, Montie J, **Shah RB**, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent gene fusion of TMPRSS2 to ETS family members of prostate cancer. Science. 2005, 130: 644-48.
28.	Varambally S, Yu Jianjun, Laxman B, Rhodes D, Mehra R, Tomlins S, **Shah RB**, Chandan U, Monson FA, Bechich MJ, Wei JT, Pienta KG, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative Genomic and Proteomic

Analysis of Prostate Cancer Reveals Signatures of Metastatic Progression. Cancer Cell. 2005; 8:393-406. (Featured as a cover article).

29. **Shah RB**, Bakshi N, Hafez KS, Wood DP, Jr, Kunju LP. Image-Guided Biopsy in the Evaluation of Renal Mass Lesions in Contemporary Urologic Practice: Indications, Adequacy, Clinical Impact and Limitations of Pathologic Diagnosis. Hum Pathol. 2005, 36, 1309-1315.

30. Begley L, Monteleon C, **Shah RB**, MacDonald JW, Macoska JA. CXCL12 Over-Expression and Secretion by Aging Fibroblasts Enhances Human Prostate Epithelial Proliferation in Vitro. Aging Cell. 2005, 4, 291-298.

31. Tomlins SA, Mehra R, Rhodes DR, **Shah RB**, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM. Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives. Neoplasia. 2006, 8 (2), 153-62.

32. Kunju LP, Mehra R, Snyder M, **Shah RB**. Prostate-Specific Antigen, High-Molecular Weight Cytokeratin (Clone 34βE12), and/or p63: An Optimal Immunohistochemical Panel to Distinguish Poorly Differentiated Prostate Adenocarcinoma (PCa) from Urothelial Carcinoma (UC). Am J Clin Pathol. 2006, 125(5):675-81.

33. De Marzo A, Platz E, Epstein JI, Ali T, Billis A, Chan T, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine S, Iczkowski K, Ittmann M, Knudsen B, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Rubin M, Samartunga H, Sebo T, Sesterhenn I, **Shah RB**, Signoretti S, Simko J, Troncoso P, Tsuzuki T, van Leenders G, Yang X, Zhou M, Figg W, Hoque A, Lucia M. A. Working Group Classification of Focal Prostate Atrophy Lesions. Am J Surg Pathol. 2006, 30(10): 1281-91.

34. De Marzo A, Platz E, Epstein JI, Ali T, Billis A, Chan T, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine S, Iczkowski K, Ittmann M, Knudsen B, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Rubin M, Samartunga H, Sebo T, Sesterhenn I, **Shah RB**, Signoretti S, Simko J, Troncoso P, Tsuzuki T, van Leenders G, Yang X, Zhou M, Figg W, Hoque A, Lucia M. A. Erratum. Working Group Classification of Focal Prostate Atrophy Lesions. Am J Surg Pathol. 2006, 30(10): 1281-91.

35. Ray ME, Mehra R, Sandler HM, Daignault S, **Shah RB**. E-Cadherin Protein Expression Predicts Salvage Radiotherapy Outcomes for Prostate Cancer. J Urol. 2006, 176(4): 1409-14.

36. Datta MW, Hernandez AM, Schlicht MJ, Kahler AJ, Degueme AM, Dhir R, **Shah RB**, Farach-Carson MC, Barrett A, Datta S. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol Cancer. 2006, 5: 9.

37. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, **Shah RB**, Chinnaiyan AM. TMPRSS2:ETV4 Gene Fusions define third molecular subtype of prostate cancer. Cancer Res. 2006, 66:(7); 3396-3400.

38. **Shah RB**, Ghosh Debashis, Elder JT. Epidermal Growth Factor Receptor (ErbB1) Expression in Prostate Cancer Progression: Correlation with Androgen Independence. The Prostate, 66(13); 1437-44, 2006.

39. Heavner SB, **Shah RB**, Moyer JS. Sclerosing mucoepidermoid carcinoma of the parotid gland. Eur Arch Otorhinolaryngol. 2006, 263 (10):955-9.

40. Bakshi N, Kunju L, Giordano T, **Shah RB**. Expression of Renal Cell Carcinoma Antigen (RCC) in Renal Epithelial and Non-Renal Tumors: Diagnostic Implications. App Immunohistochem Mol Morphol. 2007, 15(3): 310-15.

41. Havens AM, Jung Y, Sun YX, Wang J, **Shah RB**, Buhring HJ, Pienta KJ, Taichman RS. The Role of Sialomucin CD 164 (MGC-24y or Endolyn) in Prostate Cancer Metastasis. BMC Cancer. 2006, 6:195.

42. Hollingsworth JM, Miller DC, Daignault S, **Shah RB**, Hollenbeck BK. Variable Penetrance Of A Consensus Classification Scheme For Renal Cell Carcinoma. Urology. 2007 69(3):452-6.

43. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, **Shah RB**, Rubin MA, Wei JT, Chinniayan AM. Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer. Neoplasia. 2006, 8(10):885-8.

44. Perner S, Hofer MD, Kim R, **Shah RB**, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA. Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression. Hum Pathol, 2007, 38(5); 696-701. .

45. Tomlins SA, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S. M, Wei JT, Rubin MA, Pienta KJ, **Shah RB**, Chinnaiyan AM. Integrative Molecular Concepts Modeling of Prostate Cancer Progression. Nature Genetics. 2007, 39(1):45-51. (Co-senior authorship).

46. Mehra R, Tomlins SA, Shen R, Naddem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinniayan AM, **Shah RB**. Comprehensive Assessment of TMPRSS2 and ETS Family Gene Aberrations in Clinically Localized Prostate Cancer. Mod Pathol, 2007, 20(5):538-44.

47. Lee IH, Roberts R, **Shah RB**, Wojno K, Wei JT, Sandler H. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int. J Radiat Oncol Biol Phys. 2007, Mar 28.

48. Splading AC, Daignault S, Sandler HM, **Shah RB**, Pan CC, Ray ME. Percent Positive Biopsy Cores as a Prognostic Factor for Prostate Cancer Treated with External Beam Radiation. Urology. 2007, 69(5); 936-40.

49. Miller DC, Wei JT, **Shah RB**, Spencer BA, Ritchey J, Stewart AK, Dunn RL, Litwin MS. The quality of pathological care for men treated with radical prostatectomy in the United States. Cancer. 2007, 109 (12):2445-53

50. Morris DS, Tomlins SA, Rhodes DR, Mehra R, **Shah RB**, Chinnaiyan AM. Integrating biomedical knowledge to model pathways of prostate cancer progression. Cell Cycle. 2007, 6(10):1177-87.

51. Wasco M, Daignault S, Zhang Yingxi, Kunju LP, Kinnaman M, Braun T, Lee CT, **Shah RB**. Urothelial Carcinoma with Divergent Histological Differentiation (Mixed Histology) is an Independent Predictor of the Presence of Extravesical Tumor When Detected at Transurethral Resections. Urology. 2007, 70(1):69-74. (Featured as a cover article).

52. Przybycin C, Kunju LP, Wu AJ, **Shah RB**. Partial Atrophy in Prostate Needle Biopsies: A Detailed analysis of Morphology, Immunophenotype, and Cellular Kinetics. Am J Surg Pathol. 2008, 32(1):58-64.

53. Yang XJ, Zhou M, Hes Ondrej, Shen Steven, Li Ronshang, Lopez Jose, **Shah RB**, Yang Yu, Chuang ST, Lin Fan, Tretiakowa MM, Kort Eric, Teh BT. Tubulocystic Carcinoma of the Kidney – Clinicopathological and Molecular Characterization. Am J Surg Pathol. 2008, 32(2):177-87.

54. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson B, Cao X, Han B, Yu J, Way L, Montie JE, Rubin MA, Pienta KJ, Roulston D, **Shah RB**, Varambally S, Mehra R, Chinnaiyan AM. Distinct Classes of Chromosomal Rearrangement Create Oncogenic ETS Gene Fusions in Prostate Cancer. Nature. 2009, 448(7153):595-9.

55. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson B, Cao X, Han B, Yu J, Way L, Montie JE, Rubin MA, Pienta KJ, Roulston D, **Shah RB**, Varambally S, Mehra R, Chinnaiyan AM. Distinct Classes of Chromosomal Rearrangement Create Oncogenic ETS Gene Fusions in Prostate Cancer. Reply. Nature. 2009, 457(7231):E2-E3.

56. Weizer AZ, Ye Z, Hollingsworth JM, Dunn RL, **Shah RB**, Wolf JS Jr, Wei JT, Montie JE, Hollebeck BK. Adoption of new technology and healthcare quality: surgical margins after robotic prostatectomy. Urology. 70(1): 96-100.

57. Kunju LP, Wojno K, Wolf S Jr, Cheng L, **Shah RB**. Papillary Renal Cell Carcinoma with Oncocytic Cells and Non-overlapping Low-Grade Nuclei: Expanding the Morphologic Spectrum with Emphasis on Clinico-pathologic, Immunohistochemical and Molecular Features. Human Pathology. 2007, 39(1):96-101.

58. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie J, Rubin M, Pienta KJ, **Shah RB**, Chinniayan AM. Integrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression. Cancer Research. 2007, 67(17): 8229-8239.

59. Mehra R, Han B, Tomlins SA, Shen R, Wang L, Menon A, Wasco M, Shen R, Montie JE, Chinniayan AM, **Shah RB**. Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases. Cancer Research. 2007, 67(17): 7991-95.

60. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, **Shah RB**, Ghosh D, Varambally S, Chinniayan AM. Integrative Genomics Analysis Reveals Silencing of beta-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell. 2007, 12(5):419-31.

61. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, **Shah RB**, Varambally S, Pienta KJ, Chinnaiyan AM. A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Research. 2007, 67(22); 10657-10633.

62. Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, **Shah RB**, Zhang S, Brunelli M, Cheng L. Clear-Cell Papillary Renal cell Carcinoma: a Distinct Histopathological and Molecular Genetic Entity. Am J Surg Pathol. 2008, 32(8):1239-45.

63. Weizer AZ, **Shah RB**, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP, Jr., M.D. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy; Defining risk with prostate capsule sparing cystectomy. Urologic Oncology. 2007, 25:460-64.

64. Miller DC, **Shah RB**, Bruhn A, Madison R, Saigal CS. Urologic Diseases in America Project. Trends in the use of gross and frozen pathological consultations During Partial or Radical Nephrectomy for Renal Cell Carcinoma. J Urol. 2008, 179(2):461-7.

65. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Presner JR, Rubin MA, **Shah RB**, Mehra R, Chinniayan AM. Role of TMPRSS2-ETS Gene Fusion in Prostate Cancer. Neoplasia. 2008, 10(2):177-88.

66.	Shangary S, Quin D, McEachern D, Liu M, Miller RS, Qui S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, **Shah RB**, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008, 105(10):3933-8.
67.	Hall CL, Daignault SD, **Shah RB**, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008, 68(13):1396-1404.
68.	Mehra R, Tomlins SA, Wang L, Menon A, Pienta KJ, **Shah RB***, Chinniayan AM*. Characterization of TMPRSS2-ETS Gene Aberrations in Androgen Independent Metastatic Prostate Cancer. Cancer Research. 2008, 68(10):3857-90. (* Co-senior author) (Featured as a cover article).
69.	Schulte RT, Wood DP, Diagnault MS, **Shah RB**, Wei JT. Utility of Extended Pattern Prostate Biopsies for Tumor Localization: Pathologic Correlation following Radical Prostatectomy. Cancer. 2008, 113(7):1559-65.
70.	Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, CAO X, Andren O, Fall K, Johnson L, Wei JT, **Shah RB**, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjatell AS, Chinnaiyan AM. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer cell. 2008, 13(6):519-28.
71.	Mosquera JM, Perner S, Genega EM, Sandra M, Hofer MD, Mertz KD, Paris PL, Bismar TA, Ayala G, **Shah RB**, Loda M, Rubin MA. Characterization of TMPRSS-ERG Fusion High-grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. Clin Cancer Res. 2008, 14(11):3380-5.
72.	Gobbo S, Eble JN, Maclennan GT, Crignon DJ, **Shah RB**, Zhang S, Martignoni G, Brunelli M, Cheng L. Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components: The Utility of Immunohistochemical and Cytogenetical Analyses in Differential Diagnosis. Am J Surg Pathol. 2008, 32(12):1780-6.
73.	Park H, Piert MR, Khan A, **Shah R**, Hussain H, Siddiqui J, Chenvert TL, Meyer CL. Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol. 2008, 15(8):1027-39.
74.	Wu A, Kinjo LP, Cheng L, **Shah RB**. Renal Cell Carcinoma in Children and Young Adults: Analysis of Clinicopathologic, Immunohistochemical and Molecular Characteristics with an Emphasis on the Spectrum of Xp11.2 Translocation Associated and Unusual Clear Cell Type, Histopathology, 53(5): 533-44, 200.
75.	Kunju LP, Daignault S, Wei JT, **Shah RB**. Should multiple cores with prostate cancer submitted in the same container without site identifiers be assigned individual Gleason scores? Human Pathol, 40(4): 558-64, 2009.
76.	Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, **Shah RB**, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008, 68(18): 7629-37.
77.	Borofsky M, **Shah RB**, Wolf Jr JS. Nephron-Sparing Diagnosis and Management of Renal Keratinizing Desquamative Squamous Metaplasia. J Endourol. 2009, 23(1):51-5.
78.	Bradford TJ, Weizer AZ, Gilbert SM, Dunn RL, Wojno K, **Shah R**, Wood DP. Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures? Urol Oncol. 2010, 28(5):487-91
79.	**Shah RB**, Chinnaiyan AM. The Discovery of Common Recurrent TMPRSS2:ETS Gene Fusions in Prostate Cancer: Significance and Clinical Implications. Review. Adv Anat Pathol. 2009, 16(3):145-53.
80.	Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, **Shah RB**. Fluorescence in Situ Hybridization Study Shows Association of PTEN Deletion with ERG Rearrangement during Prostate Cancer Progression. Mod Pathol. 2009, 22(8):1083-93.
81.	**Shah RB**. Current Perspectives on Gleason Grading of Prostate Cancer. Arch Pathol Lab Medicine. 2009, 133(11):1810-6, Review.
82.	Mosquera JM, Mehra R, Regan M, Perner S, Genega E, Bueti G, **Shah RB**, Gaston S, Tomlins S, Wei J, Kearney M, Johnson L, Tang J, Chinnaiyan A, Rubin M, Sanda M. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009, 15(14):4706-11.
83.	Weizer AZ, Wasco MJ, Wang R, Daignault S, Lee CT, **Shah RB**. Multiple Adverse Histologic Features Increase the Odds of Understaging in Patients with T1 Bladder Cancer. J Urol. 2009, 182(1):59-65.

84. Han B, Mehra R, Suleman K, Wang L, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, **Shah RB**. Characterization of TMPRSS2: ETS Gene Fusions in Histologic Variants of Prostate Cancer. Mod Pathol. 2009, 22(9):1176-85.

85. Wasco M, Daignault S, Bradley D, **Shah RB**. Nested Variant of urothelial Carcinoma: A Clinocopathologic and Immunohistochemical Study of 30 Pure and Mixed Cases. Hum Pathol. 2010, 41(2):163-71 (Featured as a cover article).

86. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, Wood D, Johnson T, **Shah RB**, Meyer C. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009, 50(10):1585-93.

87. Zhou M, Yang XJ, Lopez JI, **Shah RB**, Hes O, Shen SS, Li R, Yang Y, Lin F, Elson P, Sercia L, Magi-Galluzzi C, Tubbs R. Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. Am J Surg Pathol. 2009, 33(12);1840-9.

88. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van de Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group: Adeniran A, Al-Ahmadie H, Algaba F, Allan R, Amin M, Barry M, Bastacky S, Baydar D, Bégin L, Berney D, Billis A, Boccon-Gibod L, Bostwick D, Brito M, Burks T, Busch C, Camparo P, Cheng L, Cohen C, Datta M, de Leval L, Delahunt B, Delprado W, Egevad L, Epstein J, Evans A, Falzarano S, Fine S, Fridman E, Furusato B, Ganji M, Glantz L, Gopalan A, Grignon D, Grobholz R, Guo C, Gupta R, Gurel B, Hailemariam S, Hakam A, Hameed O, Hansel D, Henke RP, Herawi M, Hirsch M, Huang J, Huang W, van de Kaa CH, Humphrey P, Iczkowski K, Jones E, Jones M, Jufe L, Kench J, Kim HJ, Kragel P, Kristiansen G, Leite KR, Lewin CD, Lloreta J, Lopez-Beltran A, Lucia S, Luthringer D, Magi-Galluzzi C, McCue P, McHale T, McKenney J, Merino M, Montironi R, Nesi G, Netto G, Oliva E, Oliveira P, Osunkoya A, Paner G, Parwani A, Picken M, Pizov G, Renshaw A, Ro J, Rohan S, Ronchetti R, Rubin M, Samaratunga H, Sankila A, Schned A, Sesterhenn I, Shabaik A, **Shah R**, Shanks J, Shen S, Shim J, Shiraishi T, Speights VO Jr, Srigley J, Sung MT, Suzigan S, Takahashi H, Tan PH, Tetu B, Tickoo S, Tomaszewski J, Troncoso P, Trpkov K, True L, Tsuzuki T, Turner J, van der Kwast T, Weiss M, Wheeler T, Wojno K, Volmar K, Wu CL, Yao J, Yilmaz A, Zhai J. International Society of Urological Pathology (ISUP) Consensus on Handling and Staging of Radical Prostatectomy Specimens. Working Group 5: surgical margins. Mod Pathol, 2010. 23(1):48-57.

89. **Shah RB**, Han B, Magi-Galluzzi C, Zhou M. Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies. Am J Surg Pathol. 2010, 34(4):470-7.

90. Park H, Meyer CR, Wood D, Khan A, **Shah R**, Hussain H, Siddiqui J, Seo J, Chenevert T, Piert M. Validation of Automatic Target Volume Definition as Demonstrated for (11)C-Choline PET/CT of Human Prostate Cancer Using Multi-Modality Fusion Techniques. Acad Radiol. 2010, 17(5):614-23.

91. Borza T, **Shah RB**, Ferber GJ, Wolf JS. Localized Amyloidosis of the Upper Urinary tract: A Case Series of Three Patients Managed with Reconstructive Surgery or Surveillance. J Endourol. 2010, 24(4):641-4.

92. Han B, Suleman K, Siddiqui J, Wang L, Magi-Galluzzi C, Pallnisamy N, Chinniayan AM, Zhou M, **Shah RB**. ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction between Intraductal Carcinoma of the Prostate and Cribriform High-Grade Prostatic Intraepithelial Neoplasia. Am J Surg Pathol. 2010, 34(4):478-85.

93. Djekidel M, Gordon M, **Shah RB**, Gross MD, Avram A. Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging. Thyroid. 2010, 20(4):429-33.

94. Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel D, Iczowski K, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, Ro JY, **Shah RB**, Shen SS, Tamboli P, McKenney JF. Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Genitourinary Tract among Urologic Pathologists. Am J Surg Pathol. 2010; 34(9):1367-76.

95. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer Group: Adeniran A, Al-Ahmadie H, Algaba F, Allan R, Amin M, Barry M, Bastacky S, Baydar D, Bégin L, Berney D, Billis A, Boccon-Gibod L, Bostwick D, Brito M, Burks T, Busch C, Camparo P, Cheng L, Cohen C, Datta M, de Leval L, Delahunt B, Delprado W, Egevad L, Epstein J, Evans A, Falzarano S, Fine S, Fridman E, Furusato B, Ganji M, Glantz L, Gopalan A, Grignon D, Grobholz R, Guo C, Gupta R, Gurel B, Hailemariam S, Hakam A, Hameed O, Hansel D, Henke RP, Herawi M, Hirsch M, Huang J, Huang W, van de Kaa CH, Humphrey P, Iczkowski K, Jones E, Jones M, Jufe L, Kench J, Kim HJ, Kragel P, Kristiansen G, Leite KR, Lewin CD, Lloreta J, Lopez-Beltran A, Lucia S, Luthringer D, Magi-Galluzzi C, McCue P, McHale T, McKenney J, Merino M, Montironi R, Nesi G, Netto G, Oliva E, Oliveira P, Osunkoya A, Paner G, Parwani A, Picken M, Pizov G, Renshaw A, Ro J, Rohan S, Ronchetti R, Rubin M, Samaratunga H, Sankila A, Schned A, Sesterhenn I,

Shabaik A, **Shah R**, Shanks J, Shen S, Shim J, Shiraishi T, Speights VO Jr, Srigley J, Sung MT, Suzigan S, Takahashi H, Tan PH, Tetu B, Tickoo S, Tomaszewski J, Troncoso P, Trpkov K, True L, Tsuzuki T, Turner J, van der Kwast T, Weiss M, Wheeler T, Wojno K, Volmar K, Wu CL, Yao J, Yilmaz A, Zhai J. International Society of Urological Pathology (ISUP) Consensus on Handling and Staging of Radical Prostatectomy Specimens. Working Group 3: extra prostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011; 24(1):26-38.

96. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group: Adeniran A, Al-Ahmadie H, Algaba F, Allan R, Amin M, Barry M, Bastacky S, Baydar D, Bégin L, Berney D, Billis A, Boccon-Gibod L, Bostwick D, Brito M, Burks T, Busch C, Camparo P, Cheng L, Cohen C, Datta M, de Leval L, Delahunt B, Delprado W, Egevad L, Epstein J, Evans A, Falzarano S, Fine S, Fridman E, Furusato B, Ganji M, Glantz L, Gopalan A, Grignon D, Grobholz R, Guo C, Gupta R, Gurel B, Hailemariam S, Hakam A, Hameed O, Hansel D, Henke RP, Herawi M, Hirsch M, Huang J, Huang W, van de Kaa CH, Humphrey P, Iczkowski K, Jones E, Jones M, Jufe L, Kench J, Kim HJ, Kragel P, Kristiansen G, Leite KR, Lewin CD, Lloreta J, Lopez-Beltran A, Lucia S, Luthringer D, Magi-Galluzzi C, McCue P, McHale T, McKenney J, Merino M, Montironi R, Nesi G, Netto G, Oliva E, Oliveira P, Osunkoya A, Paner G, Parwani A, Picken M, Pizov G, Renshaw A, Ro J, Rohan S, Ronchetti R, Rubin M, Samaratunga H, Sankila A, Schned A, Sesterhenn I, Shabaik A, **Shah R**, Shanks J, Shen S, Shim J, Shiraishi T, Speights VO Jr, Srigley J, Sung MT, Suzigan S, Takahashi H, Tan PH, Têtu B, Tickoo S, Tomaszewski J, Troncoso P, Trpkov K, True L, Tsuzuki T, Turner J, van der Kwast T, Weiss M, Wheeler T, Wojno K, Volmar K, Wu CL, Yao J, Yilmaz A, Zhai J. International Society of Urological Pathology (ISUP) Consensus on Handling and Staging of Radical Prostatectomy Specimens. Working Group 2: T2 sub staging and prostate cancer volume. Mod Pathol. 2011; 24(1):16-25.

97. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L. Srigley JR; ISUP Prostate Cancer Group: Adeniran A, Al-Ahmadie H, Algaba F, Allan R, Amin M, Barry M, Bastacky S, Baydar D, Bégin L, Berney D, Billis A, Boccon-Gibod L, Bostwick D, Brito M, Burks T, Busch C, Camparo P, Cheng L, Cohen C, Datta M, de Leval L, Delahunt B, Delprado W, Egevad L, Epstein J, Evans A, Falzarano S, Fine S, Fridman E, Furusato B, Ganji M, Glantz L, Gopalan A, Grignon D, Grobholz R, Guo C, Gupta R, Gurel B, Hailemariam S, Hakam A, Hameed O, Hansel D, Henke RP, Herawi M, Hirsch M, Huang J, Huang W, van de Kaa CH, Humphrey P, Iczkowski K, Jones E, Jones M, Jufe L, Kench J, Kim HJ, Kragel P, Kristiansen G, Leite KR, Lewin CD, Lloreta J, Lopez-Beltran A, Lucia S, Luthringer D, Magi-Galluzzi C, McCue P, Teresa M, McKenney J, Merino M, Montironi R, Nesi G, Netto G, Oliva E, Oliveira P, Osunkoya A, Paner G, Parwani A, Picken M, Pizov G, Renshaw A, Ro J, Rohan S, Ronchetti R, Rubin M, Samaratunga H, Sankila A, Schned A, Sesterhenn I, Shabaik A, **Shah R**, Shanks J, Shen S, Shim J, Shiraishi T, Speights VO Jr, Srigley J, Sung MT, Suzigan S, Takahashi H, Tan PH, Tetu B, Tickoo S, Tomaszewski J, Troncoso P, Trpkov K, True L, Tsuzuki T, Turner J, van der Kwast T, Weiss M, Wheeler T, Wojno K, Volmar K, Wu CL, Yao J, Yilmaz A, Zhai J. International Society of Urological Pathology (ISUP) Consensus on Handling and Staging of Radical Prostatectomy Specimens. Working Group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011; 24(1):39-47.

98. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group: Adeniran A, Al-Ahmadie H, Algaba F, Allan R, Amin M, Barry M, Bastacky S, Baydar D, Bégin L, Berney D, Billis A, Boccon-Gibod L, Bostwick D, Brito M, Burks T, Busch C, Camparo P, Cheng L, Cohen C, Datta M, de Leval L, Delahunt B, Delprado W, Egevad L, Epstein J, Evans A, Falzarano S, Fine S, Fridman E, Furusato B, Ganji M, Glantz L, Gopalan A, Grignon D, Grobholz R, Guo C, Gupta R, Gurel B, Hailemariam S, Hakam A, Hameed O, Hansel D, Henke RP, Herawi M, Hirsch M, Huang J, Huang W, van de Kaa CH, Humphrey P, Iczkowski K, Jones E, Jones M, Jufe L, Kench J, Kim HJ, Kragel P, Kristiansen G, Leite KR, Lewin CD, Lloreta J, Lopez-Beltran A, Lucia S, Luthringer D, Magi-Galluzzi C, McCue P, McHale T, McKenney J, Merino M, Montironi R, Nesi G, Netto G, Oliv E, Oliveira P, Osunkoya A, Paner G, Parwani A, Picken M, Pizov G, Renshaw A, Ro J, Rohan S, Ronchetti R, Rubin M, Samaratunga H, Sankila A, Schned A, Sesterhenn I, Shabaik A, **Shah R**, Shanks J, Shen S, Shim J, Shiraishi T, Speights VO Jr, Srigley J, Sung MT, Suzigan S, Takahashi H, Tan PH, Tetu B, Tickoo S, Tomaszewski J, Troncoso P, Trpkov K, True L, Tsuzuki T, Turner J, van der Kwast T, Weiss M, Wheeler T, Wojno K, Volmar K, Wu CL, Yao J, Yilmaz A, Zhai J. International Society of Urological Pathology (ISUP) Consensus on Handling and Staging of Radical Prostatectomy Specimens. Working Group 1: specimen handling. Mod Pathol. Jan 2011; 24(1):6-15.

99. Carvalho J, Wasco M, Kunju LP, Thomas DG, **Shah RB**. Cluster Analysis of Immunohistochemical Profiles Delineates CK7, Vimentin, S100A1 and C-kit (CD 117) as an Optimal Panel in the Differential Diagnosis of Renal Oncocytoma from its Mimics. Histopathology. 20011, 58(2):169-79.

100. Williamson SR, Zhang S, Lopez-Beltran A, **Shah RB**, Montironi R, Tan P, Wamg M, Baldrige LA, MacLennan GT, Cheng L. Lymphoepithelioma-like Carcinoma of the Urinary Bladder: Clinicopathologic, Immunohistochemical, and Molecular Features. Am J Surg Pathol. 2011; 35(4):474-83.

101. Mehra R, Kumar-Sinha C, Lonigro RJ, Shankar S, Jing X, Phillips NE, Han B, Cao X, Smith DC, **Shah RB**, Chinnaiyan AM, Pienta KJ. Characterization of bone metastasis from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011, 17(12):3924-32.

102. Garcia-Parra R, Wood D, **Shah RB**, Siddique J, Hussain H, Park H, Desmond T, Meyer C, Piert M. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging. 2011, 38(10):1816-23.

103. Carvalho J, Thomas DG, McHugh J, **Shah RB**, Kunju LP. p63, CK7, Vimentin, PAX8 and INI-1: An Optimal Immunohistochemical Panel to Distinguish Poorly Differentiated Urothelial Cell Carcinoma from High-grade Tumors of the Renal Collecting System. Histopathology. 2012, 60(4):597-608.

104. Park H, Wood D, Hussain H, Meyer CR, **Shah RB**, Johnson TD, Chenevert T, Piert M. Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer. J Nucl Med. 2012, 53(4):546-51.

105. **Shah RB**, Montgomery JS, Montie JE, Kunju LP. Variant Histological Differentiation in Urothelial Carcinoma is Under-recognized in Community Practice: Impact of Mandatory Central Pathology Review at a Large Referral Hospital, Urol Oncol. 2013, 31(8):1650-5.

106. Gupta R, Billis A, **Shah RB**, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol. 2012, 36(9):1265-78.

107. **Shah RB**, Zhou M. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate. Review. Adv Anat Pathol. 2012, 19(4):270-9.

108. **Shah RB**, Tadros Y, Brummell B, Zhou M. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alph-methylacyl-CoA-racemase markers. Human Pathol. 2013, 44(5):786-94.

109. **Shah RB**. Clinical Application of Novel ERG immunohistochemistry in Prostate Cancer Diagnosis and Management. Review. Adv Anat Pathol. 2013, 20(2): 117-24.

110. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel: Abraham A, Adeniran A, Ahmed K, Al Ahmadie H, Algaba F, Allan R, Amin M, Argani P, Axcrona U, Barry M, Baydar D, Bégin L, Berney D, Bethwaite P, Billis A, Birbe R, Bonsib S, Bostwick D, Brimo F, Cathro H, Chen YB, Cheng L, Cheville J, Mee Cho Y, Chuang AY, Cohen C, Crist H, Delahunt B, Delprado W, Deng FM, Egevad L, Epstein J, Evans A, Fadare O, Fajardo D, Falzarano S, Fine S, Fleming S, Fridman E, Furusato B, Ganji M, Ghayouri M, Giannico G, Gokden N, Griffiths D, Grignon D, Gupta N, Hameed O, Hes O, Hirsch M, Huang J, Huang W, Hulsbergen-van de Kaa C, Humphrey P, Hussein S, Iczkowski K, Jimenez R, Jones E, Jufe LI, Kench J, Kida M, Kristiansen G, Kunju LP, Lane Z, Latour M, Lewin C, Lie K, Lloreta J, Loftus B, Lopez-Beltran A, Maclean F, Magi-Galluzzi C, Martignoni G, McHale T, McKenney J, Merino M, Miller R, Miyamoto H, Moch H, Montironi R, Murphy H, Nacey J, Nazeer T, Nesi G, Netto G, Nichols P, O'Donnell M, Olgac S, Orozco R, Osunkoya A, Ozagari A, Pan CC, Parwani A, Perry-Keene J, Petraki C, Picken M, Pyda-Karwicka M, Reuter V, Rezaei K, Rioux- Leclercq N, Robinson B, Rohan S, Ronchetti R, Russell L, Samaratunga H, Scarpelli M, Shabaik A, **Shah R**, Shanks J, Shen S, Shevchuk M, Sibony M, Srigley J, Srinivasan B, Susani M, Suzigan S, Sweet J, Takahashi H, Tamboli P, Tan PH, Tickoo S, Trias I, Trpkov K, True L, Tsuzuki T, Vakar- Lopez F, Van der Kwast T, Wang C, Warren A, Yao J, Yilmaz A, Zhao J, Zhou M, Zynger D. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. Oct 2013; 37(10):1469-89.

111. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; ISUP Renal Tumor Panel: Abraham A, Adeniran A, Ahmed K, Al Ahmadie H, Algaba F, Allan R, Amin M, Argani P, Axcrona U, Barry M, Baydar D, Bégin L, Berney D, Bethwaite P, Billis A, Birbe R, Bonsib S, Bostwick D, Brimo F, Cathro H, Chen YB, Cheng L, Cheville J, Mee Cho Y, Chuang AY, Cohen C, Crist H, Delahunt B, Delprado W, Deng FM, Egevad L, Epstein J, Evans A, Fadare O, Fajardo D, Falzarano S, Fine S, Fleming S, Fridman E, Furusato B, Ganji M, Ghayouri M, Giannico G, Gokden N, Griffiths D, Grignon D, Gupta N, Hameed O, Hes O, Hirsch M, Huang J, Huang W, Hulsbergen-van de Kaa C, Humphrey P, Hussein S, Iczkowski K, Jimenez R, Jones E, Jufe LI, Kench J, Kida M, Kristiansen G, Kunju LP, Lane Z, Latour M, Lewin C, Lie K, Lloreta J, Loftus B, Lopez-Beltran A, Maclean F, Magi-Galluzzi C, Martignoni G, McHale T, McKenney J, Merino M, Miller R, Miyamoto H,

Moch H, Montironi R, Murphy H, Nacey J, Nazeer T, Nesi G, Netto G, Nichols P, O'Donnell M, Olgac S, Orozco R, Osunkoya A, Ozagari A, Pan CC, Parwani A, Perry-Keene J, Petraki C, Picken M, Pyda-Karwicka M, Reuter V, Rezaei K, Rioux- Leclercq N, Robinson B, Rohan S, Ronchetti R, Russell L, Samaratunga H, Scarpelli M, Shabaik A, **Shah R**, Shanks J, Shen S, Shevchuk M, Sibony M, Srigley J, Srinivasan B, Susani M, Suzigan S, Sweet J, Takahashi H, Tamboli P, Tan PH, Tickoo S, Trias I, Trpkov K, True L, Tsuzuki T, Vakar- Lopez F, Van der Kwast T, Wang C, Warren A, Yao J, Yilmaz A, Zhao J, Zhou M, Zynger D. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. Oct 2013; 37 (10):1490-504.

112. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR; ISUP Renal Tumor Panel: Abraham A, Adeniran A, Ahmed K, Al Ahmadie H, Algaba F, Allan R, Amin M, Argani P, Axcrona U, Barry M, Baydar D, Bégin L, Berney D, Bethwaite P, Billis A, Birbe R, Bonsib S, Bostwick D, Brimo F, Cathro H, Chen YB, Cheng L, Cheville J, Mee Cho Y, Chuang AY, Cohen C, Crist H, Delahunt B, Delprado W, Deng FM, Egevad L, Epstein J, Evans A, Fadare O, Fajardo D, Falzarano S, Fine S, Fleming S, Fridman E, Furusato B, Ganji M, Ghayouri M, Giannico G, Gokden N, Griffiths D, Grignon D, Gupta N, Hameed O, Hes O, Hirsch M, Huang J, Huang W, Hulsbergen-van de Kaa C, Humphrey P, Hussein S, Iczkowski K, Jimenez R, Jones E, Jufe LI, Kench J, Kida M, Kristiansen G, Kunju LP, Lane Z, Latour M, Lewin C, Lie K, Lloreta J, Loftus B, Lopez-Beltran A, Maclean F, Magi-Galluzzi C, Martignoni G, McHale T, McKenney J, Merino M, Miller R, Miyamoto H, Moch H, Montironi R, Murphy H, Nacey J, Nazeer T, Nesi G, Netto G, Nichols P, O'Donnell M, Olgac S, Orozco R, Osunkoya A, Ozagari A, Pan CC, Parwani A, Perry-Keene J, Petraki C, Picken M, Pyda-Karwicka M, Reuter V, Rezaei K, Rioux- Leclercq N, Robinson B, Rohan S, Ronchetti R, Russell L, Samaratunga H, Scarpelli M, Shabaik A, **Shah R**, Shanks J, Shen S, Shevchuk M, Sibony M, Srigley J, Srinivasan B, Susani M, Suzigan S, Sweet J, Takahashi H, Tamboli P, Tan PH, Tickoo S, Trias I, Trpkov K, True L, Tsuzuki T, Vakar- Lopez F, Van der Kwast T, Wang C, Warren A, Yao J, Yilmaz A, Zhao J, Zhou M, Zynger D. Handling and staging of renal cell carcinoma: the international Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. Oct 2013; 37(10):1505-17.

113. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel: Abraham A, Adeniran A, Ahmed K, Al Ahmadie H, Algaba F, Allan R, Amin M, Argani P, Axcrona U, Barry M, Baydar D, Bégin L, Berney D, Bethwaite P, Billis A, Birbe R, Bonsib S, Bostwick D, Brimo F, Cathro H, Chen YB, Cheng L, Cheville J, Mee Cho Y, Chuang AY, Cohen C, Crist H, Delahunt B, Delprado W, Deng FM, Egevad L, Epstein J, Evans A, Fadare O, Fajardo D, Falzarano S, Fine S, Fleming S, Fridman E, Furusato B, Ganji M, Ghayouri M, Giannico G, Gokden N, Griffiths D, Grignon D, Gupta N, Hameed O, Hes O, Hirsch M, Huang J, Huang W, Hulsbergen-van de Kaa C, Humphrey P, Hussein S, Iczkowski K, Jimenez R, Jones E, Jufe LI, Kench J, Kida M, Kristiansen G, Kunju LP, Lane Z, Latour M, Lewin C, Lie K, Lloreta J, Loftus B, Lopez-Beltran A, Maclean F, Magi-Galluzzi C, Martignoni G, McHale T, McKenney J, Merino M, Miller R, Miyamoto H, Moch H, Montironi R, Murphy H, Nacey J, Nazeer T, Nesi G, Netto G, Nichols P, O'Donnell M, Olgac S, Orozco R, Osunkoya A, Ozagari A, Pan CC, Parwani A, Perry-Keene J, Petraki C, Picken M, Pyda-Karwicka M, Reuter V, Rezaei K, Rioux- Leclercq N, Robinson B, Rohan S, Ronchetti R, Russell L, Samaratunga H, Scarpelli M, Shabaik A, **Shah R**, Shanks J, Shen S, Shevchuk M, Sibony M, Srigley J, Srinivasan B, Susani M, Suzigan S, Sweet J, Takahashi H, Tamboli P, Tan PH, Tickoo S, Trias I, Trpkov K, True L, Tsuzuki T, Vakar- Lopez F, Van der Kwast T, Wang C, Warren A, Yao J, Yilmaz A, Zhao J, Zhou M, Zynger D. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol, Oct 2013; 7(10):1518-31.

114. **Shah RB**, Tadros Y. Adenocarcinoma of the Prostate with Gleason Pattern 5 on Core Biopsy: Frequency of Diagnosis, Morphologic Subpatterns and Relation to Pattern Distribution Based on the Modified Gleason Grading System. Human Pathol, 2014, 45(11): 2263-9.

115. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, **Shah RB**, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Ann Diagn Pathol. 2014 18(6):332-42.

116. Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, **Shah RB**, Epstein JI, De Marzo AM, Lotan TL. Utility of PTEN and ERG Immunostaining for

Distinguishing High-grade PIN from Intraductal Carcinoma of the Prostate on Needle Biopsy. Am J Surg Pathol. 2015 39(2):169-78.

117. Gopal P, **Shah RB**. Primary Anal Canal Syphilis in Men: The Clinicopathologic Spectrum of an Easily Overlooked Diagnosis. Arch Pathol Lab Med. 2015, 139(9):1156-60.

118. **Shah RB**, Bentley J, Jeffery Z, DeMarzo AM. Heterogeneity of PTEN and ERG Expression in Prostate Cancer on Core Needle Biopsies: Implications for Cancer Risk Stratification and Biomarker Sampling. Human Pathol. 2015, 46(5): 698-706.

119. Begley LA, Kasina S, **Shah RB**, Macoska JA. Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent. Am J Clin Exp Urol 2015 3(2): 91-9 eCollection.

120. **Shah RB**, Li J, Cheng L, Egevad L, Deng FM, Fine SW, Kunju LP, Melamed J, Mehra R, Osunkoya AO, Paner, G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, Zhou M. Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: An interobserver reproducibility study among urologic pathologists. Am J Surg Pathol. 2015, 39(9): 1242-9.

121. Zhou M, Li J, Cheng L, Egevad L, Deng FM, Kunju LP, Magi-Galluzzi C, Melamed J, Mehra R, Mendrinos S, Osunkoya AO, Paner, G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, **Shah RB**. Grading Poorly Formed Prostate Adenocarcinoma as Gleason Pattern 4 on Needle Biopsy: An Interobserver Reproducibility Study among Urologic Pathologists and Recommendations. Am J Surg Pathol. 2015, 39(10):1331-9.

122. **Shah RB**, Li J, Dhanani N, Mendrinos S. ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia. Urol Oncol. 2015; 34(3):120.e1-7.

123. **Shah RB**, Zhou M. Recent Advances in Prostate Cancer Pathology: Modified Gleason Grading and More. Review. Path Int. 2016, 66(5):260-72.

124. **Shah RB**, Leandro G, Romerocases G, Bentley J, Yoon J, Mendrinos S, Tadros Y, Tian W, Lash R. Improvement in inter-observer reproducibility in resolving an "Atypical glands suspicious for prostate cancer" diagnosis in prostate biopsies using a novel "Diseased focused diagnostic review" quality process. Human Pathol. 2016, 56: 155-62 (Featured as Top 10 (#3) Best articles of 2016 by Pathology Editor's Choice by MDLinx Pathology).

125. Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsay SJ, Paul A, Broses LJ, **Shah RB**, Kunju LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KM, Keller ET, Thomas DG, Nagrath S, Morgan TM, Day ML. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017, 77(1):74-85.

126. Yu H, Hickman R, Li J, Kong M, **Shah RB**, Zhou M, Melamed J, Deng F-M. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathological Characteristics as Intraductal Carcinoma of the Prostate. Am J Surg Pathol. 2017, 41(4):550-556.

127. Tian W, Dorn D, Wei S, Sanders RD, Matoso A, **Shah RB**, Gordetsky J. GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. Histopathology. 2017, 71 (1): 150-155.

128. **Shah RB**, Yoon J, Liu G, Tian W. Atypical Intraductal Proliferation and Intraductal Carcinoma of the Prostate on Core Needle Biopsy: A Comparative Clinicopathological and Molecular Study with a Proposal to Expand Morphological Spectrum of Intraductal Carcinoma. Histopathology, 2017, 71(5):693-702.

129. Venkadakrishnan VB, DePriest AD, Kumari S1, Senapati , Ben-Salem, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, **Shah RB**, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38(23):4496-4511

130. **Shah RB**, Shore KT, Yoon J, Mendrinos S, McKenney JK, Tian W. PTEN Loss in Prostatic Adenocarcinoma Correlates with Specific Adverse Histologic Features (Intraductal Carcinoma, Cribiform Gleason Pattern 4 and Stromogenic Carcinoma). Prostate, 2019,79 (11):1267-1273

131. **Shah RB**, Nguyen JK, Przybycin CG, Reynolds JP, Cox R, Myles J, Klein E, McKenney J. Atypical Intraductal Proliferation Detected in Prostate Needle Biopsy is a Marker of Unsampled Intraductal Carcinoma and Other Adverse Pathological Features. Histopathology. 2019, 75(3):346-353

132. Gandhi JS, Smith SC , Paner GP, McKenney JK, Sekhri Radhika, Osunkoya AO, Baras As, DeMarzo AM, Cheville JC, Jimenez RE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Sirohi D, Kaushal Seema, Sangoi A, Robinson BD, Kweldam CF, Humphrey PA, Hansel DE, Schultz L, Magi-Galluzi C, Przybycin CG, **Shah RB**, Mehra R, Kunju LP, Aron M, Kryvenko ON, Kench JG, Kuroda N, Tavora F, Kwast TV, Grignon DJ, Epstein JI, Reuter VE, Amin MB. Reporting Practices and Resources Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists. Am J Surg Pathol. 2020 44(5):673-680

133. **Shah RB**, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, Cox RM, Rashid-Kolvear F, Weindel MD, Farkas DH, Trpkov K, Mckenney JK. "Renal Cell Carcinoma with Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020 44(5):571-581

134. Epstein JI., Amin MB., Fine SW., Algaba F, Aron M, Baydar DE., Lopez BA, Brimo F, Cheville JC., Colecchia M, Comperat E, Werneck da Cunha I, Delprado W, DeMarzo AM., Giannico GA., Gordetsky JB., Guo CC., Hansel DE., Hirsch MS., Huang J, Humphrey PA., Jimenez RE., Khani F, Kong Q, Kryvenko ON., Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ., Nguyen JK., Osunkoya AO., Parwani A, Robinson BD., Rubin MA., **Shah RB.,** So JS., Takahashi H, Tavora F, Tretiakova MS., True L, Wobker SE., Yang XJ., Zhou M, Zynger DL., Trpkov K. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med, 2021, 145(4):461-493. PMID: 32589068

135. Przybycin C, McKenney J, Nguyen J, **Shah RB**, Umar S, Harik L, Shih I, Cox R. Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. Am J Surg Pathol, 2020, 44(10):1322-1330

136. Fine SW, Trpkov K, Amin MB., Fine SW., Algaba F, Aron M, Baydar DE., Lopez BA, Brimo F, Cheville JC., Colecchia M, Comperat E, Werneck da Cunha I, Delprado W, DeMarzo AM., Giannico GA., Gordetsky JB., Guo CC., Hansel DE., Hirsch MS., Huang J, Humphrey PA., Jimenez RE., Khani F, Kong Q, Kryvenko ON., Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ., Nguyen JK., Osunkoya AO., Parwani A, Robinson BD., Rubin MA., **Shah RB.,** So JS., Takahashi H, Tavora F, Tretiakova MS., True L, Wobker SE., Yang XJ., Zhou M, Zynger DL., Epstein JI. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urol Oncol 2021,39(5):295.e1-295.e8

137. Tian W, Shore K, **Shah RB.** Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for reporting urine cytology: A single institutional study of more than 27,000 cases. Cancer Cytopathol, 2020, 129(2):114-120. PMID: 32931158

138. Trpkov K, Williamson S, Gill AJ, Adeniran A, Agaimy A, Alaghehbandan R, Amin M, Argani P, Chen Y, Cheng L, Epstein J, Cheville J, Comperat E, Cunha I, Gordetsky J, Gupta S, He H, Hirsch M, Humphrey P, Kapur P, Kojima F, Lopez J, Maclean F, Magi-Galluzzi C, McKenney J, Mehra R, Menon S, Netto G, Przybycin C, Rao P, RAO Q, Reuter VE, Saleeb R, **Shah RB**, Smith S, Tickoo S, Tretiakova M, Verkarre V, Wobker S, Zhou M, and Ondrej H. Novel, Emerging and Provisional Renal Entities: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Mod Pathol 34(6):1167-1184

139. Trpkov K, Hes Ondřej, Williamson S, Gill AJ, Adeniran A, Agaimy A, Alaghehbandan R, Amin M, Argani P, Chen Y, Cheng L, Epstein J, Cheville J, Comperat E, Cunha I, Gordetsky J, Gupta S, He H, Hirsch M, Humphrey P, Kapur P, Kojima F, Lopez J, Maclean F, Magi-Galluzzi C, McKenney J, Mehra R, Menon S, Netto G, Przybycin C, Rao P, RAO Q, Reuter VE, Saleeb R, **Shah RB**, Smith S, Tickoo S, Tretiakova M, Verkarre V, Wobker S, Zhou M, and Gill AJ. New Developments in Existing WHO Entities and Evolving Molecular Concepts: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Mod Pathol 2021, 34(7):1392-1424

140. Correction to: Trpkov K, Williamson S, Gill AJ, Adeniran A, Agaimy A, Alaghehbandan R, Amin M, Argani P, Chen Y, Cheng L, Epstein J, Cheville J, Comperat E, Cunha I, Gordetsky J, Gupta S, He H, Hirsch M, Humphrey P, Kapur P, Kojima F, Lopez J, Maclean F, Magi-Galluzzi C, McKenney J, Mehra R, Menon S, Netto G, Przybycin C, Rao P, RAO Q, Reuter VE, Saleeb R, **Shah RB**, Smith S, Tickoo S, Tretiakova M, Verkarre V, Wobker S, Zhou M, and Ondrej H. Novel, Emerging and Provisional Renal Entities: The Genitourinary Pathology Society (GUPS) Update on Renal Neoplasia. Mod Pathol 34(5):1037

141. Costa DN, Qi C, **Shah RB**, Pedrosa I. Gleason Grade Group Concordance Between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathology: A Comparison Between In-Bore MRI-Guided and MRI-TRUS Fusion Prostate Biopsies. Radiol Imaging Cancer 2021, 3(2):e200123

142. Varma M, **Shah RB**, Williamson SR, Berney DM. 2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Arch 2021, 478(4):813-815

143. Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC,

Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, **Shah RB**, Shariat SF, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol. 2021 28(4):196-208

144. Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, **Shah RB**, Shariat S, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol. 2021 28(4):179-195

145. **Shah RB**, Cai Q, Aron M, Berney DM, Cheville JC, Deng FM, Epstein J, Fine SW, Genega EM, Hirsch MS, Humphrey PA, Gordetsky J, Kristiansen G, Kunju LP, Magi-Galluzzi C, Gupta N, Netto GJ, Osunkoya AO, Robinson BD, Trpkov K, True LD, Troncoso P, Varma M, Wheeler T, Williamson SR, Wu A, Zhou M. Diagnosis of "Cribriform" Prostatic Adenocarcinoma: An Interobserver Reproducibility Study among Urologic Pathologists with Recommendations. Am J Cancer Res 2021;11(8):3990-4001

146. Hannan R, Salamekh S, Desai N, Garant A, Folkert M, Costa D, Mannala S, Ahn C, Mohamad O, Laine A, Kim D, Dickinson T, Taj G, **Shah RB**, Wang J, Jia X, Choy H, Roehrborn CG, Lotan Y, Timmerman RD. Stereotactic Ablative Radiotherapy for High-Risk Prostate Cancer-a Prospective Multi-level MRI-based Dose Escalation Trial. Int J Radiat Oncol Biol Phys 2021; Online ahead of print

147. **Shah RB.** Renal Cell Carcinoma With Fibromyomaotus stroma – The whole story. Adv Anat Pathol 2022 29(3):168-177

148. **Shah RB**, Palsgrove DN, Desai NB, Gagan J, Mennie A, Raj G, Hannan R. Enrichment of "Cribriform" morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. Mod Pathol 2022, Online ahead of print

149. Mohanty SK, Lobo A, Williamson SR, **Shah RB**, Trpkov K, Varma M, Sirohi D, Aron M, Kandukari SR, Balzer BL, Luthringer DL, Ro J, Osunkoya AO, Desai S, Menon S, Nigam LK, Sardana R, Roy P, Kaushal S, Midha D, Swain M, Ambekar A, Mitra S, Rao V, Soni S, Jain K, Diwaker P, Pattnaik N, Sharma S, Chakrabarti I, Sable M, Jain E, Jain D, Samra S, Vankalkunti M, Mohanty S, Parwani AV, Sancheti S, Kumari N, Jha S, Dixit M, Malik V, Arora S, Munjal G, Gopalan A, Magi-Galluzzi C, Dhillon J. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among 39 Genitourinary Pathologists. Int J Surg Pathol. 2022, Online ahead of print

150. Costa DN, Meng X, Tverye A, Bagrodia A, Recchimuzzi DZ, Xi Y, Arraj P, **Shah RB**, Subramanian N, Diaz de Leon A, Roehrborn CG, Rofsky NM, Chen H, Pedrosa I. Preoperative Multiparametric Prostate Magnetic Resonance Imagin Structured Report Informs Risk for Positive Apical Surgical Margins During Radical Prostatectomy. J Comput Assist Tomogr. 2022, Online ahead of print

151. Qi C, Costa DN, Metter CK, Goldberg K, Roehrborn CG, Cadeddu J, Pedrosa I, Meng X, Mostardeiro TR, **Shah RB**. Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform Gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole-mount histopathology. Urol Oncol. 2022, Online ahead of print

152. Hogan K, McKenney JK, Cox RM, Nguyen JK, **Shah RB**, Billings SD, Przybycin CG. Myxoid pseudotumor involving the renal sinus: Clinicopathologic study of 33 cases supporting a distinct benign non-neoplastic lesion. Am J Surg Pathol, 2022, Online ahead of print. PMID: 36040041

153. Alaghehbandan R, Agaimy A, Ali L, Alvarado-Cabrero I, Amin MB, Boudova L, Caliò A, Comperat EM, Damjanov I, Daum O, Farcas M, Gatalica Z, Gill AJ, Hartmann A, Hayes MM, Hora M, Kojima F, Kristiansen G, Kuroda N, López JI, Maclean F, Magi-Galluzzi C, Martignoni G, McKenney JK, Michalová K, Michal M, Mohanty SK, Netto GJ, Ohashi R, Ondič O, Osunkoya AO, Gomez MDPM, Petersson F, Picken MM, Pivovarcikova K, Rogala J, **Shah RB**, Siadat F, Skenderi F, Sperga M, Suster SM, Svajdler M, Tretiakova M, Trpkov K, Ulamec M, Williamson SR, Yang XJ, Zhou M, Vranic S, Vujanic G, Michal M. A tribute to Prof. Ondrej Hes, MD, PhD (1968-2022). Mod Pathol. 2022 35(12):2023-2024

154. Cai Q, Shah RB. Cribriform Lesions of the Prostate Gland. Surg Pathol Clin 2022 15(4):591-608

155. Zhou M, Amin A, Rao P, Siadat F**, Shah RB**. Should Grade Group 1 Prostate Cancer Be Reclassified as "Non-cancer"? A Pathology Community Perspective. Urol Oncol, 2022

156. Li J, Ettel M, Amin A, Bhalla R, Das K, Deng FM, Lee, P, Matoso A, Melamed J, Mendrinos S, Tian W, Yaskiv O, **Shah RB**, Zhou M. Interobserver Reproducibility of Quantifying Gleason Pattern 4 Cancer in Prostate Biopsy: Implications for Clinical Practice. Journal of Clinical and Translational Pathology, 12/27/2022

Reviews, Chapters, Monographs, and Editorials

1. **Shah RB**, Amin MB. "Disorders of Penis, Urethra, and Scrotum", In Genitourinary Pathology. A volume in the series "Foundations in Diagnostic Pathology". Elsevier Science, 2006.
2. Wasco M, **Shah RB**. "Benign Diseases and Neoplasms of Penis". In Surgical Pathology Clinics: Current Concepts in Genitourinary Pathology. 2008.
3. Weizer AZ, Gilbert SM, **Shah RB**, Wood DP Jr. Management and controversies of HGPIN and ASAP on prostate biopsy: In Prostate Biopsy: Indications, Techniques, and Complications. Humana Books Contemporary Clinical Urology Series. Marc, 2008.
4. Wu A, **Shah RB**. "Translocation associated renal cell carcinoma" eMedicine Pathology, 2009.
5. **Shah RB**. "Disorders of Penis, Urethra, and Scrotum", In 2nd edition, Genitourinary Pathology. A volume in the series "Foundations in Diagnostic Pathology". Zhou M, Magi-Galluzzi (Eds), Elsevier Science, 2014.
6. **Shah RB**, Bhalla R. "New Molecular Markers of Diagnosis and Prognosis in Prostate Cancer", In Genitourinary Pathology. Practical Advances. Magi-Galluzzi, Przybycin, Christopher (Eds.) Springer, 2015.
7. Nguyen J**, Shah RB**. Differential Diagnosis in Surgical Pathology: Tumors and Their Mimickers. Foundation in diagnostic pathology series, scheduled to publish 2022.
8. Cai Qi, **Shah RB**. Cribriform lesions of the prostate gland. Surgical Pathology Clinics, 12/2022
Editorials
1. **Shah RB**. Editorial Comment. J Urol. 2008, 179(5):1755.
2. Varma M, **Shah RB**, Williamson S, Berney D. 2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Archive, 2022
Letters
1. **Shah RB**. Reply to "Low-grade intraductal carcinoma of the prostate: An idea whose time has not yet come": Evidence-based medicine suggests that the time is now. Histopathology. 2017, 71(5):839-840.
Abstracts
1. Wang Q, **Shah R**, Giraldo A, David C, Kong Y. Induction of autoimmune thyroiditis by unique human thyroglobulin epitopes in H2E transgenic mice. FASEB J; Mar 1998; 12(5): 6080A
2. Wang Q, **Shah R**, Giraldo A, David C, Kong Y. HLA-DQ8 Transgenic class II-negative mice develop autoimmune thyroiditis after induction with human thyroglobulin. FASEB J; Mar 1999; 13: A1000.
3. **Shah R**, Mucci N, Amin A, Macoska J, Rubin M. Proliferative Inflammatory Atrophy in Prostate Cancer: Implications as a potential Neoplastic Precursor. Mod Pathol. Jan 13, 2000; 1, 108A.
4. Day M, Vallorosi C, Rashid M, Day K, Zhao X, **Shah R**, Amin A, Macoska J, Rubin M. E-Cadherin down Regulation in Prostate Carcinoma through post-translation Protein Truncation. Mod Pathol, Jan 13, 2000, No.1, 98A.
5. **Shah R**, Amin A, Macoska J, Rubin M. Molecular Profiling to Distinguish Flat Urothelial Carcinoma in Situ from Reactive Changes after BCG Therapy. Modern Pathol, 14(10):714, Jan 2001, Lab Invest 81; 10:714A.
6. **Shah R**, Kaldjian E, Gieseg M, Figurski J, Redman B, Rubin M. Epidermal Growth Factor Receptor Expression is Up Regulated in Clear Cell Renal Carcinoma: Immunohistochemical Tissue Array Confirmation of cDNA Expression Analysis. Modern Pathol, l 14(1): 714, Jan 2001, Lab Invest, 81(1): 713A.
7. **Shah R**, Kaldjian E, Gieseg M, Figurski J, Redman B, Rubin M. Epidermal Growth Factor Receptor Expression is Up Regulated in Clear Cell Renal Carcinoma: Immunohistochemical Tissue Array Confirmation of cDNA Expression Analysis. Mod Pathol, 165, 5, 52A, Jan 2001.
8. Zhou M, **Shah R**, Proverbs-Singh T, Rubin M. Lack of Association between Prostate Carcinoma Nuclear Grading and Prostate Specific Antigen Recurrence Following Radical Prostatectomy. Modern Pathol 14(1): 762A Jan 2001, Lab Invest 81(1): 762 Jan 2001 (Also submitted for publication as peer reviewed original article in the Journal of Urology, Mar 29, 2001).
9. Dunn R, **Shah R**, Zhou M, Ingold C, Rubin M. Global Gleason Score, Highest Core Gleason Score, or Weighted Gleason Score: What Gleason Score Should Be Reported in Prostate Needle Biopsies? Mod Pathol, 15(1): 669A, Jan 2002.
10. **Shah R**, Ingold C, Rubin M. Prostate Adenocarcinoma with Foamy Gland Features Diagnosed on Needle Biopsies: Prevalence and Clinico-Pathological Associations. Mod Pathol, 15(1): 775A, Jan 2002.

11. Zhou M, **Shah R**, Ingold C, Rubin M. Simultaneous Evaluation for Presence of Nerve and Perineural Invasion on Prostate Needle Biopsy Improve Predictability for Extraprostatic Extension on Radical Prostatectomy. Mod Pathol, 15(1): 790A, Jan 2002.
12. Zhou M, Dhanasekaran S, **Shah R**, Pienta K, Chinnaiyan A, Rubin M. ∝-Methylacyl-CoA Racemase (AMACR) Is Highly Specific for Prostate Cancer as Determined by Expression and Tissue Microarray Analysis. Mod Pathol, 15(1): 791A, Jan 2002.
13. **Shah R**, Zhou M, LeBlanc M, Rubin M. Comparison of the Basal Cell-Specific Markers, p63 and 34βE12, in the Diagnosis of Prostate Cancer. Mod Pathol, 15(1): 754A, Jan 2002.
14. Dash A, **Shah R**, Dhanasekaran S, Chinnaiyan A, Rubin M. The Molecular Profile of Prostatic Hypertrophy Using cDNA and Tissue Microarrays: What Genes Distinguish It from Prostate Cancer? Mod Pathol, 15(1): 664A, Jan 2002.
15. **Shah R**, Rubin M. TMA TECHNOLOGY: A Powerful Tool for Validation of Newly Discovered Genes. Lead Article in Advance for Administrators, 2002.
16. **Shah R**, Zhou M, LeBlanc M, Rubin M. Comparison of the Basal Cell-Specific Markers, p63 and 34βE12, in the Diagnosis of Prostate Cancer. AJESP, 26(9), 1161A, Sep 2002.
17. Kunju L, Rubin M, Shen R, Ingold C, Chinnaiyan A, **Shah R**. Diagnostic Utility of the Monoclonal Antibody P504S in the Work Up of Prostate Carcinoma. Mod Pathol, 16(1): 719A, Jan 2003.
18. **Shah R**, Kunju L, Shen R, LeBlank M, Rubin M. Utility of Basal Cell Cocktail (p63+34βE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. Mod Pathol, 16(1): 726A, Jan 2003.
19. **Shah R**, Kunju L, Shen R, LeBlank M, Rubin M. Utility of Basal Cell Cocktail (p63+34βE12) in the Diagnosis of Atypical Prostate Glandular Proliferations. Vol 169, No. 4, J Urol, 2002 (463 A)
20. Kunju L, Rubin M, **Shen R**, Ingold C, Chinnaiyan A, Shah R. Comparison of Monoclonal Antibody (P504S) and Polyclonal Antibody to ∝-Methylacyl-CoA Racemase in Benign, Atypical and Malignant Prostate Tissues. Mod Pathol, 16(1): 718A, Jan 2003.
21. O'Toole J, Norman S, Kriesche H, **Shah R**, Johnson K, Arenas J, Cibrik D. IVIG for the Treatment of Transplant BK Nephropathy.
22. Zhou M, **Shah R**, Shen R, Rubin M. Basal Cell Cocktail (34βE12+p63) Improves the Detection of Prostate Basal Cells. Mod Pathol, 16(1): 807A, Jan 2003.
23. **Shah R**, Mehra R, Zhou M, Chinnaiyan A, Harwood J, Pienta K, Rubin M. The Varied Morphological and Immunophenotypic Spectrum of Hormone Refractory Metastatic Prostate Cancer: Lesson From A Rapid Autopsy Program University of Michigan School of Medicine, Ann Arbor, MI and Brigham and Womens Hospital, Harvard Medical School, Boston, MA. Mod Pathol, 17(1):177A, Jan 2004.
24. Snyder M, Mehra R, Kunju L, Montie J, **Shah R**. Departments of Pathology and Urology, University of Michigan, Ann Arbor, MI. Utility of a Novel Immunohistochemical (IHC) Panel (PSA, High Molecular Weight Cytokeratin and/or p63) in the differentiation of Poorly differentiated Prostate Adenocarcinoma (PCa) from Urothelial Carcinoma (UC). Mod Pathol, 17(1):178A, Jan 2004.
25. Kunju L, Snyder M, Lee C, Montie J, **Shah R**, University of Michigan, Ann Arbor, MI. Cytokeratin 20 and Ki-67 as Markers of Urothelial Dysplasia. Modern Pathol, 17(1): 163A, Jan 2004.
26. Azabdaftari G, **Shah R**, Bismar T, Kim R, Zerkowski M, Rimm D, Pienta K, Rubin M. Androgen Receptor Expression in Hormone Refractory Prostate Cancer from a Rapid Autopsy Series: Quantitative Subcellular Localization Using AQUA. Mod Pathol, 18(1):5A, Jan 2005.
27. Baig M, Kunju L, Schervish E, **Shah R**, Wojno K. Gleason Grading Multifocal Adenocarcinoma in Prostatectomy Specimens: Implications for Grading Needle Biopsies. Mod Pathol, 18(1):127A, Jan 2005.
28. Bakshi N, Kunju L, Wood Jr D, **Shah R**. Minimally Invasive Prostatectomy (Laproscopic and Robot-Assisted): Clinicopathological Characteristics of 82 Cases from a Single Institution. Mod Pathol, 18(1):128A, Jan 2005.
29. Bakshi N, Kunju L, Giordano T, **Shah R**. Expression of Renal Cell Carcinoma Antigen (RCC) in Renal Epithelial and Non-Renal Tumors: Diagnostic Implications. Mod Pathol, 18(1):128A, Jan 2005.
30. De Marzo A, Platz E, Epstein J, Billis A, Chan T, Cheng L, Datta M, Ertoy-Baydar D, Farre X, Fine S, Iczkowski K, Ittmann M, Knudsen B, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Rubin M, Sebo T, Sesterhenn I, **Shah R**, Signoretti S, Simko J, Troncoso P, Tsuzuki T, van Leenders G, Yang X, Zhou M, Figg W, Hoque A, Lucia M. Interobserver Reproducibility of a Proposed Classification of Focal Prostate Atrophy Lesions. Mod Pathol, 18(1):135A, Jan 2005.
31. Kunju L, Chinnaiyan A, **Shah R**. Comparison of Utility of Polyclonal and Monoclonal Antibody to alpha Methyl Acyl Co A Racemase (AMACR) in Work-up of Prostate Cancer. Mod Pathol, 18(1):150A, Jan 2005.

32. Kunju L, Bakshi N, Poisson L, Hafez K, Wojno K, **Shah R**. Morphologic Subtyping of Papillary Renal Cell Carcinoma: Clinicopathologic and Immunohistochemical Analysis. Mod Pathol, 18(1):150A, Jan 2005.
33. Kunju L, Bakshi N, Poisson L, Hafez K, Wojno K, **Shah R**. Morphologic Subtyping of Papillary Renal Cell Carcinoma: Clinicopathologic and Immunohistochemical Analysis. J Urol, 2005.
34. Kunju L, Bakshi N, Wood D, Hafez K, **Shah R**. Role of Percutaneous Image-Guided Renal Biopsy (IGRB) in the Management of Renal Masses: Adequacy, Accuracy and Limitations of Pathologic Diagnosis. Mod Pathol, 18(1):151A, Jan 2005.
35. **Shah R**, Ghosh D, Pienta K, Elder J. Epidermal Growth Factor Receptor (ErbB1) Expression in Prostate Cancer Progression: Correlation with Androgen Independence. Mod Pathol, 18(1):163A, Jan 2005.
36. **Shah R**, Chinnaiyan A, Mehra R, Varambally S, Shen R, Harwood J, Bismar T, Kim R, Pienta K, Rubin M. Heterogeneous Androgen Receptor (AR) Protein Expression in Metastatic Androgen-Independent Prostate Cancer: Implications for Complex AR Mechanisms in the Progression to Androgen Independent Prostate Cancer. Mod Pathol, 18(1):163A, Jan 2005.
37. Ray, Michael E.; Spalding, Aaron C.; Faruzzi, Stephanie; **Shah, Rajal**; Pan, Charlie C; Sandler, Howard M. Percent Positive Cores and Proportion Cancer Volume as Prognostic Factors for Prostate Radiation Therapy. ASTRO, 2005.
38. Ray M, Chinnaiyan AM, Wei JT, Mehra R, Sandler HM, Faruzzi S, Wojno KJ, **Shah RB**. Strategies for Prostate Cancer Biomarker Studies in Radiation Therapy Patients. 13th SPORE National Meeting, Biomarkers Session II, Washington DC, Jul 11, 2005.
39. Mehra R, Tomlins SA, Rhodes DR, Cao X, Chinnaiyan A, **Shah RB**. Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro dissected Prostate tissues. Mod Pathol, 19(1):149A, Jan 2006. (Recipient of Storbell Orbison award and International Society of Urological Pathology best abstract award presented by a trainee (R Mehra) at the United States and Canadian Academy of Pathology (USCAP), Atlanta, 2006.
40. Ray M, Mehra R, Sandler H, Daignault S, **Shah RB**. E-Cadherin Protein Expression of Prostate Adenocarcinoma Independently Predicts Salvage Radiotherapy Outcomes. Mod Pathol, 19(1):157A, Jan 2006.
41. Mehra R, Poisson L, Varambally S, Tomlins S, Kunju L, Ghosh D, Chinnaiyan A, **Shah RB**. Stathmin is Over Expressed in Metastatic Prostate Cancer: Implications in Prostate Cancer Progression. Mod Pathol, 19(1):149A, Jan 2006.
42. **Shah RB**, Weizer A, Dunn R, Bakshi N, Wei J, Wojno K, Montie J, Wood D. Neurovascular Tissue Thickness on Prostatectomy Specimens is Less Predictive of Quality of Life Outcomes than Surgeon's Description of Nerve sparing Procedure. Mod Pathol, 19(1):160A, Jan 2006.
43. **Shah RB**, Amin A, Mehra R, Braun T, Redman B. High Carbonic Anhydrase (CA) IX Protein Tissue Expression Predicts Response to Interleukin (IL)-2 based Therapy for Advanced Renal Cell Carcinoma Patients. Mod Pathol, 19(1):160A, Jan 2006.
44. Wasco M, Braun T, Przybycin C, Kunju L, Lee C, **Shah RB**. Urothelial Carcinomas with Mixed Histology: Incidence, Clinicopathological Spectrum, and Biological Significance. Mod Pathol, 19(1):168A, Jan 2006.
45. Weizer A, **Shah RB**, Gilbert SB, Daignault S, Lee CT, Montie JE, Wood DP. Presence, Location and Significance of Prostate Cancer in Patients undergoing Radical Cystoprostatectomy: Feasibility of Prostate Capsule Sparing Cystectomy. J Urol, 175(4), 1234A, 2006.
46. Mehra R, Tomlins SA, Rhodes DR, Cao X, Chinnaiyan A, **Shah RB**. Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro dissected Prostate tissues. J Urol, 175(4), 411A, 2006.
47. **Shah RB**, Wasco M, Braun T, Przybycin C, Kunju L, Lee C. Urothelial Carcinomas with Mixed Histology: Incidence, Clinicopathological Spectrum, and Biological Significance. J Urol, 175(4), 990A, 2006.
48. **Shah RB**, Amin A, Mehra R, Braun T, Redman B. High Carbonic Anhydrase (CA) IX Protein Tissue Expression Predicts Response to Interleukin (IL)-2 based Therapy for Advanced Renal Cell Carcinoma Patients. J Urol, 175(4), 725A, 2006.
49. Hafez K, Wood DP, Jr, Nghiem HV, Higgins E, **Shah RB**, Daignault, S, Wolf SJ. Success of Radiofrequency ablation (RFA) as assessed by radiographic and histologic criteria. J Urol, 175(4), 1122A, 2006.
50. Macoska JA, Begley L, Monteleon C, MacDonald JW, **Shah RB**. CXCL12 over-expression and secretion by aging fibroblasts stimulates human prostate epithelial proliferation in vitro. J Urol, 175(4), 1442A, 2006.
51. Wu AJ, Friedman J, Hussain M, **Shah RB**. Neoadjuvant Docetaxel and Capecitabine in Patients with High Risk Prostate Cancer: Morphologic Features and Immunoprofile of Postchemotherapy Specimens. Mod Pathol, 20(2): 184A, Mar 2007.

52. Wu AJ, Kunju LP, **Shah RB**. Renal cell carcinoma in children and young adults: Clinico-pathological Spectrum with an Emphasis on Translocation Associated Carcinomas. Mod Pathol, 20(2): 183A, March 2007.
53. Przybycin C, Kunju LP, Wu AJ, **Shah RB**. Partial Atrophy in Prostate Needle Biopsies: A Detailed Characterization of Morphology, Immunophenotype, and Proliferation Status. Mod Pathol, 20(2): 171A, Mar 2007.
54. Mehra R, Tomlins S, Shen R, Wang L, Wei JT, Pienta KJ, Rubin M, Chinniayan AM, **Shah RB**. Molecular Signature and Clinical Implications of TMPRSS2 and ETS Transcription Family Genes Fusions in a Surgical Cohort of American Men Treated for Clinically Localized Prostate Cancer. Mod Pathol, 20(2); 163A, Mar 2007.
55. Fine SW, Trock B, Reuter VE, Ayala G, Cheville JC, Fearn P, Jenkins RB, Knudsen BS, Loda M, Netto GJ, Said J, **Shah RB**, Simpko J, Troncoso P, True LD, Yang XJ, Rubin MA, DeMarzo AM. Effects of tissue processing on biomarker Analysis in Prostate Needle Biopsies: A Multi-institutional Study. Mod Pathol, 20(2): 146A, Mar 2007.
56. Hall CL, **Shah RB**, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from the primary tumor to metastasis, American Association of Cancer Research Centennial Meeting, Apr 2007.
57. Weizer AZ, Ye Z, Hollingsworth JM, Gilbert SM, Dunn RL, **Shah RB**, Wolf JS Jr, Wei JT, Montie JE, Hollenbeck BK. Adoption of New Technology and Health Care Quality: Surgical Margins Following Robotic Prostatectomy. J Urol, 177(4):557, Apr 2007.
58. Miller DC, Litwin MS, **Shah RB**, Madison R, Saigal CS. Trends in the use of intraoperative pathological consultation during radical prostatectomy. J Urol, 177(4):563A, Apr 2007.
59. Miller DC, Wei JT, **Shah RB**, Spencer BA, Ritchey J, Stewart AK, Dunn RL, Litwin MS. The quality of pathological care for men treated with radical prostatectomy in the United States. J Urol, 177(4):1033A, Apr 2007.
60. Hollingsworth JM, Miller DC, Daignault S, **Shah RB**, Hollenbeck BK. Variable Penetrance Of A Consensus Classification Scheme For Renal Cell Carcinoma. J Urol, 177(4):649A, April, 2007.
61. Morris DS, Tomlins SA, Laxman B, Mehra R, **Shah RB**, Rubin MA, Wei JT, Chinniayan AM. Adoption of a new technology and health care quality: Surgical margins following robotic prostatectomy. J Urol, 177(4):1703A, Apr, 2007.
62. Mehra R, Tomlins S, Shen R, Wang L, Wei JT, Pienta KJ, Rubin M, Chinniayan AM, **Shah RB**. Comprehensive assessment of TMPRSS2 and ETS Transcription Family Genes Fusions in a Surgical Cohort of American Men Treated for Clinically Localized Prostate Cancer. J Urol, 177(4):1436A, Apr, 2007 (Abstract selected as American Urology Association (AUA) (highlight).
63. Yang XJ, Zhou M, Hes O, Shen S, Li R, Lopez J, **Shah RB**, Y Yang, Chauang ST, Lin F, Tretiakova MM, Kort EJ, Teh BT. Tubulocystic Carcinoma of the Kidney: Clinicopathological, Immunohistochemical and Molecular characterization. Modern Pathology, 21: 872: 191A, Jan, 2008.
64. Mehra R, Tomlins S, Chinniayan AM, **Shah RB**. TMPRSS2: ETS Gene fusions in androgen independent metastatic prostate cancers: An association of TMPRSS2: ERG fusions through intronic deletions and molecular evidence of clonal expansion. Modern Pathol, 21: 170A: 775, Jan, 2008. (Winner of the Stowell-Orbison Certificate of Merit, USCAP, 2008).
65. Wasco M, Weizer A, Daignault S, Montie JE, Lee C, **Shah RB**. Assessment of Pathologic Risk Factors for Understaging in Patients with Clinical T1 Bladder Cancers. Modern Pathology, 21: 866: 170A, Jan, 2008.
66. Wu A, Wasco M, Daignault S, Kunju LP, Wood DP Jr, Wei JT, **Shah RB**. Correlation of biopsy and radical prostatectomy Gleason score in contemporary extended ≥12 core biopsies practice: Improved correlation with biopsy worst Gleason score. Laboratory Investigation, 88: 869: 190A, Jan, 2008.
67. Mehra R, Han Bo, Tomlins S, Wang Lei, Menon A, Wasco MJ, Shen R, Montie JE, Chinniayan AM, **Shah RB**. Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular evidence for an Independent Group of Diseases. Modern Pathol, 67: 7991: 17A, Jan, 2008.
68. Kunju LP, Diagnauli S, Wei JT, **Shah RB**. Should multiple cores with prostate cancer submitted in the same container be assigned individual Gleason scores? Laboratory Investigation, 88: 746: 164A, Jan 2008.
69. Mosquera JM, Mehra R, Regan M, Genega EM, Gaston S, Perner S, Connor M, Bueti G, Tomlins DA, **Shah RB**, Wei J, Kearney M, Johnson LA, Tang JM, Chinnaiyan AM, Sandra MG, Rubin MA. Prevalence of TMPRSS2-ERG fusion prostate cancer in men undergoing prostate biopsy in the United States. Laboratory Investigation, 88: 786: 172A, Jan, 2008.

70. Sercia L, Yang XJ, Lopez, JI, Hes O, Shen S, Li R, **Shah RB**, Yang Y, Lin F, Tubbs R, Zhou M. Renal tubulocystic carcinoma is related to papillary renal cell carcinoma: Cytogenetic and histologic evidence. Laboratory Investigation, 88: Supplement 1: 180A, Jan, 2008.
71. Wasco MJ, Weizer A, Daignault S, You L, Montie JE, Lee CT, **Shah RB**. Assessment of pathologic risk factors for understanding in patients with clinic T1 bladder cancer. Laboratory Investigation, 88: Supplement 1: 189A, Jan, 2008.
72. Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, **Shah RB**, Zhang S, Brunelli M, Cheng L. Heat shock proteins 27, 60, and 70 as prognostic markers of prostate cancer. Laboratory Investigation, 88: 714: 157A, Jan, 2008.
73. Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacL3ennan GT, **Shah RB**, Zhang S, Brunelli M, Gheng L. Renal papillary clear cell tumor is a distinct entity in the spectrum of renal cell neoplasia: An immunohistochemical and cytogenic analysis. Modern Pathol, 21(1); 715: 157A, Jan, 2008.
74. Gobbo S, Eble JN, Maclennan GT, Grignon DJ, **Shah RB**, Zhang S, Martignoni G, Brunelli M, Cheng L. Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components: Diagnostic Utility of Cytogenetical Analyses. Anticancer Research 28 5(C);, 2008.
75. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, **Shah RB**, Loda M, Rubin MA. Characterization of TMPRSS2-Erg fusion high-grade prostatic intraepithelial neoplasia (HGPIN) and potential clinical implications. Modern Pathol, 21(1): 784: 172AS, Jan, 2008.
76. Sercia L, Yang XJ, Lopez JI, Hes O, Shenn S, Li R, **Shah RB**, Yang Y, Lin F, Tubbs R, Zhou M. Renal tubulocystic carcinoma is related to papillary renal cell carcinoma: cytogenetic and histological evidence. Laboratory Investigation, 88(1): 824: 180A, Jan, 2008.
77. Weizer AZ, Ye Z, Hollingsworth JM, Dunn RL, **Shah RB**, Wolf JS Jr., Wei JT, Montie JE, Hollenbeck BK. Adoption of new technology and healthcare quality: Surgical margins after robotic prostatectomy. Urol Oncol, 26(2): 223-4A, March, 2008.
78. **Shah RB**, Daignault S, Kunju LP, Wood DP Jr., Wei JT. Significance of Tertiary Pattern 5 in Prostate Needle Biopsies with Gleason Score 3+4 or 4+3 Prostate Cancer: Pathologic Correlation Following Radical Prostatectomy, In press, Mod Pathol and Laboratory Investigation, 2009.
79. Mehra R, Han B, Lonigro R, Suleman K, Tomlins S, Palanisamy N, Wang L, Menon A, Hamstra D, Chinnaiyan AM, **Shah RB**. Assessment of Utility of TMPRSS2:ERG Gene Aberrations To Predict Salvage Radiotherapy Prostate Cancer Outcomes. In press, Mod Pathol and Laboratory Investigation, 2009.
80. Han B, Mehra R, Palanisamy N, Suleman K, Zhou M, Chinnaiyan A, **Shah RB**. Comprehensive Assessment of TMPRSS2 and ETS Family Molecular Aberrations in Histologic Variants of Prostate Carcinoma. In press, Mod Pathol and Laboratory Investigation, 2009.
81. Han B, Mehra R, Palanisamy N, Chinnaiyan AM, **Shah RB**. Comprehensive FISH Assessment Shows Association of PTEN Deletion with ERG Rearrangement during Prostate Cancer Development. In press, Mod Pathol and Laboratory Investigation, 2009.
82. Wasco M, Bradley D, **Shah RB**. Nested Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. In press, Mod Pathol and Laboratory Investigation, 2009.
83. Wasco M, Carvalho J, Siddiqui J, Kunju LP, Thomas D, **Shah RB**. Analysis of Novel Immunohistochemical Markers with a Cluster Analysis Approach to Define an Optimal Panel for the Differential Diagnosis of Renal Epithelial Neoplasms with Eosinophilic Cytoplasm. In press, Mod Pathol and Laboratory Investigation, 2009.
84. Zhou M, Magi-Galluzzi C, **Shah RB**. Atypical Cribriform Lesions of the Prostate: Implications for Diagnosis in Prostate Biopsies. In press, Mod Pathol and Laboratory Investigation, 2009.
85. Vankalakunti M, Gown AM, Gupta, **Shah RB**, Parakh RS, Westfall DE, Amin M, Luthringer DJ, Goldstein LC, Amin MB. An Analysis of INI1 Nuclear Expression in Collecting Duct Carcinoma (CDC) and Renal Medullary Carcinoma (RMC): Diagnostic and Pathogenetic Implications. Modern Pathology, 23: 225A-225A 1006 Suppl. / Laboratory Investigation, 90: 225A-225A 1006 Suppl. Feb 2010.
86. Vankalakunti M, Westfall DE, Parakh RS, Gupta R, **Shah RB**, Amin M, Gown AM, Goldstein LC, Amin MB. Immunohistochemical (IHC) Expression of Ulex Europaeus Agglutinin-1 (UEA-1) in the Spectrum of Adult Renal Epithelial Neoplasms – A Study of 165 Cases. Modern Pathology, 23: 225A-225A 1005 Suppl. / Laboratory Investigation, 90: 225A-225A 1005 Suppl. Feb 2010.
87. Shukla A, Carvalho J, **Shah RB**, Kunju LP. Unclassified Renal Cell Carcinoma: Clinico-Pathologic and Immunohistochemical Analysis. Modern Pathology, 23: 219A-219A 979 Suppl. / Laboratory Investigation, 90: 219A-219A 979 Suppl. Feb 2010.

88. Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE, Iczkowski KA, Ro JY, Lopez-Beltran A, Oliva E, Paner GP, Reuter VE, **Shah RB**, Shen SS, Tamboli P, McKenney JK. Interobserver Reproducibility (IOR) in the Diagnosis of Invasive Micropapillary Carcinoma (MPC) of the Genitourinary Tract Among Expert Urologic Pathologists. Modern Pathology, 23:216A-216A 965 Suppl. / Laboratory Investigation, 90: 216A-216A 965 Suppl. Feb 2010.
89. Mehra R, Han B, Kumar-Sinha C, Jing X, Cao X, Granger J, Shanker S, Smith DC, **Shah RB**, Chinnaiyan AM, Pienta KJ. Identification and Characterization of Viable Bone Metastases from Rapid Autopsies of Androgen Independent Prostate Cancer Patients. Modern Pathology, 23: 206A-206A 916 Suppl. / Laboratory Investigation, 90: 206A-206A 916 Suppl. Feb 2010.
90. Han B, Suleman K, Chinnaiyan AM, Zhou M, **Shah RB**. Characterization of ERG Gene Aberrations in Atypical Cribriform Lesions of the Prostate. Modern Pathology 23:195A-195A 864 Suppl. / Laboratory Investigation, 90: 195A-195A Suppl. Feb 2010.
91. Hameed O, Dailey VL, Al-Ahmadie HA, Amin MB, Bismar TA, Cheng L, Hansel DE, Humphrey PA, McKenney JK, Netto GJ, Paner GP, Ro J, **Shah RB**, Trpkov K, Zhou M. Interobserver Variability in Determining Carcinoma Extent Based on Percentage in Radical Prostatectomy (RP) Specimens. Modern Pathology, 23: 195A-195A 863 Suppl. / Laboratory Investigation, 90: 195A-195A 863 Suppl. Feb. 2010.
92. Carvalho JC, Thomas, DG, McHugh, JB, **Shah RB**, Kunju LP. P63 Is Useful in Distinguishing Collecting Duct Renal Carcinoma from Its Morphologic Mimics. Modern Pathology, 23:182A-183A 806 Suppl. / Laboratory Investigation, 90: 182A-183A 806 Suppl. Feb 2010.
93. Kunju LP, **Shah RB**. Variant Histologic Differentiation in Urothelial Carcinoma is Frequently Under-Recognized and Documented in Community Practice. Modern Pathology 23:201A-201A 894 Suppl. / Laboratory Investigation 90: 201A-201A 894 Suppl. Mar 2010.
94. Williamson SR, Zhang S, Lopez-Beltran A, **Shah RB**, Montiron R, Tan P, Wamg M, Baldrige LA, MacLennan GT, Cheng L. Lymphoepithelioma-like Carcinoma of the Urinary Bladder: Clinicopathologic, Immunohistochemical, and Molecular Features. Modern Pathology, 24:230A 973, 2011.
95. Mehra R, Asangani I, Lonigro R, Cao X, Philips NE, Suleman K, Varambally S, Rubin MA, **Shah RB**, Pienta KJ. MMSET is associated with prostate cancer progression and overexpressed in androgen independent metastatic prostate cancer. Modern Pathology, 24: 210A 888, 2011.
96. **Shah RB**, Lonigro Robert, Brummell B, Siddiqui J, Spaulding B, Chinniayan A, Mehra R. Antibody based detection of ERG gene fusions in prostate cancer: An Immunohistochemical study comparing C- and N-terminus ERG antibodies. Modern Pathology 25: 240A 2012.
97. Tadros Y, Brummell B, Zhou M, **Shah RB**. How often does ERG contribute to resolving an "Atypical Glands Suspicious for Cancer" diagnosis in prostate biopsies beyond that provided by basal cell and Alpha-Methylacyl-CoA-Racemase (AMACR) markers? Modern Pathology 25: 244A, 2012.
98. **Shah RB**, Tadros Y. Incidence and Clinicopathological Characteristics of Gleason Pattern 5 Prostate Cancer in Contemporary Needle Biopsies Series: A Prospective Study. Mod Pathol 27, Supplement 2: 263A, 2014.
99. **Shah RB**, DeMarzo A. Heterogeneity of PTEN and ERG biomarkers expression in prostate cancer needle biopsies with more than one core positive: Implications for biomarkers sampling strategy. MP79-13 The Journal of Urology 19(4); e934-e935, Apr 2014.
100. **Shah RB**, DeMarzo A. Heterogeneity of PTEN and ERG biomarkers expression in prostate cancer needle biopsies with more than one core positive: Implications for biomarkers sampling strategy. Mod Pathol 27, Supplement 2: 260A, 2014.
101. Zhou M, Li J, Cheng L, Egevad L, Deng FM, Kunju LP, Magi-Galluzzi C, Melamed J, Mehra R, Mendrinos S, Osunkoya AO, Paner, G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, **Shah R**. Interobserver reproducibility in grading "Poorly Formed Glands" as Gleason pattern 4 prostate cancer among urologic Pathologists. Mod Pathol 28, Supplement 2, 271A, 2015.
102. **Shah R**, Nicolau A, Moss T, Mendrinos S. PTEN protein loss and genomic deletions in prostate cancer: A comparative study of immunohistochemistry and four-color FISH assay. Mod Pathol 28, Supplement 2, 259A, 2015.
103. **Shah R**, Li J, Cheng L, Egevad L, Deng FM, Fine SW, Kunju LP, Melamed J, Mehra R, Osunkoya AO, Paner, G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, Zhou M. Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: An interobserver reproducibility study among urologic pathologists. Mod Pathol 28, Supplement 2, 259A, 2015.
104. Mendrinos S, Hansen Monica, **Shah R**. Predictive value of pathologic parameters and ERG oncoprotein expression in the stratification of prostate cancer risk associated with diagnosis of High-grade prostatic intraepithelial neoplasia (HGPIN) in prostate needle biopsy. MP86-02 The Journal of Urology 193(4);e1075, Apr 2015.

105. **Shah R**, Mendrionos S. Predictive value of pathologic parameters and ERG oncoprotein expression in the stratification of prostate cancer risk associated with diagnosis of High-grade prostatic intraepithelial neoplasia (HGPIN) in prostate needle biopsy. Mod Pathol 28, Supplement 2, 245A, 2015.
106. Li J, Amin A, Bhalla R, Das K, Deng FM, Lee, P, Matoso A, Melamed J, Mendrinos S, Tian W, Yaskiv O, **Shah R**, Zhou M. Quantifying Gleason pattern 4 prostate cancer in prostate needle biopsy: An Interobserver study (979). Mod Pathol, 2016.
107. Li J, **Shah R**, Amin A, Bhalla R, Das K, Deng FM, Lee, P, Matoso A, Melamed J, Mendrinos S, Tian W, Yaskiv O, Zhou M. Diagnostic accuracy of sub patterns of Gleason pattern 4 prostate cancer morphological sub patterns (977). Mod Pathol, 2016.
108. Tian W, Kroman E, Flejter WL, **Shah R**. Isolated 9p21 deletion detected by UroVysion fluorescence in-situ hybridization in urine samples: A study of 69 cases with emphasis on clinicopathological features and outcome (1058). Mod Pathol, 2016.
109. Hickman R, Yu H, Kong M, **Shah R**, Zhou M, Melamed J, Deng FM. Atypical cribriform lesion of the prostate shares similar ERG and PTEN expression patterns as intraductal carcinoma of the prostate and is associated with a higher stage and grade than invasive cancer alone (949). Mod Pathol, 2016.
110. **Shah R**, Leandro G, Bentley J, Chatterjee M, Romerocases G, Tian W, Tadros Y, Yoon J, Mendrinos S. Diagnostic of limited prostate adenocarcinoma on core needle biopsy: An improvement of interobserver reproducibility using comprehensive morphological and molecular criteria (1041). Mod Pathol, 2016.
111. Li J, Bu F, Deng FM, Lee P, Melamed J, **Shah R**, Zhou M. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands (PINATYP): Reappraisal of diagnostic criteria (978). Mod Pathol, 2016.
112. **Shah R**, Tian W, Zhou M, Li J. High grade prostatic intraepithelial neoplasia with adjacent small atypical glands (PINATYP) on core needle biopsy: A clinicopathologic analysis of 54 cases with emphasis on predictors of prostate cancer (1042). Mod Pathol, 2016.
113. **Shah R**, Shore K, Yoon J, Tian W, Mendrinos S. Morphologic correlates of PTEN loss prostate cancer. Mod Pathol, 2018.

Books/Textbooks

1.	**Shah RB**, Zhou M. "Interpretation of Prostate Needle Biopsies: An Illustrated Guide" Publisher: Springer, October 2011.
2.	**Shah RB**, Zhou M. "Interpretation of Prostate Needle Biopsies: An Illustrated Guide" Publisher: Springer, 2nd edition, August 2019.

Proceedings of Meetings

1. A multi-parametric study of colorectal adenocarcinomas of adolescents and young adults: comparisons with adenocarcinoma of the older age group". Presentation at XVI International Cancer Congress, New Delhi, October 1994.
2. "Histological and Histochemical Characterization of Intraluminal Seminal Vesicle Secretions: Particular Emphasis on its Crystalloid Morphology" at American Society of Clinical Pathologist Meeting, New Orleans, October 1999.
3. "Proliferative Inflammatory Atrophy in Prostate Cancer: Implications as a Potential Neoplastic Precursor" at 89th Annual United States and Canadian Academy of Pathology, New Orleans, March, 2000.
4. "Molecular Profiling to Distinguish Flat Urothelial Carcinoma in Situ from Reactive Changes after BCG Therapy" at 90th Annual United States and Canadian Pathology Meeting, Atlanta, March 2001.
5. "Epidermal Growth Factor Receptor Expression is Up-Regulated in Clear Cell Renal Carcinoma: Immunohistochemical Tissue Array Confirmation of cDNA Expression Analysis" at 90th Annual United States and Canadian Pathology, Atlanta, March 2001; and also at 2001 Annual Meeting of American Urological Association, Anaheim, CA, June 4, 2001.
6. "Comparison of the Basal Cell-Specific Markers, 34βE12 and p63, in the Diagnosis of Prostate Cancer." United States and Canadian Academy of Pathology, Chicago, February, 2002.
7. "Diagnostic Utility of Basal Cell Cocktail (p63+34βE12) in the Diagnosis of Atypical Prostate Glandular Proliferations". United and Canadian Academy of Pathology, Washington D.C., March, 2003.
8. "Diagnostic Utility of Basal Cell Cocktail (p63+34βE12) in the Diagnosis of Atypical Prostate Glandular Proliferations" American Urology Association Meeting, Chicago, April, 2003.

9. E-Cadherin Protein Expression of Prostate Adenocarcinoma Independently Predicts Salvage Radiotherapy Outcomes, The United States and Canadian Academy of Pathology, Atlanta, February 14, 2006.
10. Neurovascular Tissue Thickness on Prostatectomy Specimens is Less Predictive of Quality of Life Outcomes than Surgeon's Description of Nerve Sparing Procedure. The United States and Canadian Academy of Pathology, Atlanta, February 15, 2006.
11. High Carbonic Anhydrase (CA) IX Protein Tissue Expression Predicts Response to Interleukin (IL)-2 based Therapy for Advanced Renal Cell Carcinoma Patients. The United States and Canadian Academy of Pathology, Atlanta, February 14, 2006.
12. High Carbonic Anhydrase (CA) IX Protein Tissue Expression Predicts Response to Interleukin (IL)-2 based Therapy for Advanced Renal Cell Carcinoma Patients. The American Urology Association meeting, Atlanta, May 22, 2006.
13. Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro dissected Prostate tissues. The American Urology Association meeting, Atlanta, May 21, 2006.
14. Urothelial Carcinomas with Mixed Histology: Incidence, Clinicopathological Spectrum, and Biological Significance. The American Urology Association meeting, Atlanta, May 22, 2006.
15. Defining Prostate Cancer Progression by Molecular Profiling of Laser Capture Micro Dissected Prostate Tissues. The SPORE meeting, Baltimore, July 21, 2006.
16. "Comprehensive assessment of TMPRSS2 and ETS gene fusion assessment in clinically localized prostate cancer"- The American Urology Association (AUA) meeting, Anaheim, CA, May 22, 2007 (Selected as AUA highlights).
17. "Comprehensive assessment of TMPRSS2 and ETS gene fusion assessment in clinically localized prostate cancer"- The 3rd Michigan Urology Symposium, Ann Arbor, MI, June 12, 2007.
18. "Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular evidence for an Independent Group of Diseases" – 97th annual meeting, United States and Canadian Academy of Pathology, Denver, CO, 2008.
19. "Assessment of Pathologic Risk Factors for Under Staging in Patients with Clinical T1 Bladder Cancers" - 97th annual meeting, United States and Canadian Academy of Pathology, Denver, CO, 2008.
20. "Characterization of TMPRSS2-ETS Gene Aberrations in Androgen Independent Metastatic Prostate Cancer" – Platform presentation, The American Urology Association (AUA) meeting, Orlando, FL, May 19, 2008.
21. "Significance of Tertiary Pattern 5 in Prostate Needle Biopsies with Gleason Score 3+4 or 4+3 Prostate Cancer: Pathologic Correlation Following Radical Prostatectomy, March 11th, 98th annual meeting, United States and Canadian Academy of Pathology, Boston, MA, 2009.
22. "Nested Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Analysis of 33 cases", The American urology association (AUA) meeting, Chicago, IL, April 27, 2009.
23. "Significance of Tertiary Pattern 5 in Prostate Needle Biopsies with Gleason Score 3+4 or 4+3 Prostate Cancer: Pathologic Correlation Following Radical Prostatectomy, The American urology association (AUA) meeting, Chicago, IL, April 29, 2009.
24. "ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction between Intraductal Carcinoma of the Prostate and Cribriform High-Grade Prostatic Intraepithelial Neoplasia" March 22nd, 99th annual meeting, United States and Canadian Academy of Pathology, Washington DC, 2010.
25. "Variant (Divergent) Histologic Differentiation in Urothelial Carcinoma is Frequently Under-recognized and Under-reported in Community Practice, The American Urology Association (AUA) meeting, San Francisco, CA, May 31, 2010.
26. "Antibody-Based Detection of ERG Gene Fusions in Prostate Cancer: An Immunohistochemical study Comparing C- and N-terminus ERG Antibodies". March 19th, 101st annual meeting, United States and Canadian Academy of Pathology, Vancouver, BC, Canada. 2012.
27. "How Often Does ERG Contribute to Resolving an "Atypical Glands Suspicious for Cancer" Diagnosis in Prostate Biopsies Beyond That Provided by Basal Cell and Alpha-Methylacyl-CoA-Racemase (AMACR) Markers?" March 19th, 101st annual meeting, United States and Canadian Academy of Pathology, Vancouver, BC, Canada. 2012.
28. "Incidence and Clinicopathological Characteristics of Gleason Pattern 5 Prostate Cancer in Contemporary Needle Biopsies Series: A Prospective Study". Poster presentation. The United States and Canadian Academy of Pathology Meeting, San Diego, CA, 2014.

29. "Heterogeneity of PTEN and ERG biomarkers expression in prostate cancer needle biopsies with more than one core positive: Implications for biomarkers sampling strategy". Poster presentation. The United States and Canadian Academy of Pathology Meeting, San Diego, CA, 2014.
30. "Heterogeneity of PTEN and ERG biomarkers expression in prostate cancer needle biopsies with more than one core positive: Implications for biomarkers sampling strategy". Moderated poster presentation. The American Urology Association meeting, Orlando, FL, 2014.
31. "Predictive Value of Pathologic Parameters and ERG Oncoprotein Expression in the Stratification of Prostate Cancer Risk Associated with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) Diagnosis". Poster presentation. The United States and Canadian Academy of Pathology Meeting, Boston, MA, 2015.
32. "Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy: An interobserver reproducibility study among urologic pathologists". GU proffered papers, platform presentations. The United States and Canadian Academy of Pathology Meeting, Boston, MA, 2015.
33. "Predictive Value of Pathologic Parameters and ERG Oncoprotein Expression in the Stratification of Prostate Cancer Risk Associated with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) Diagnosis". Moderated poster presentation. The American Urology Association meeting, New Orleans, LA, 2015.
34. "Diagnosis of Limited Prostate Adenocarcinoma on Core Needle Biopsy: An improvement of interobserver reproducibility using comprehensive morphological and molecular criteria". Poster presentation. The United States and Canadian Academy of Pathology Meeting, Seattle, WA, 2016.
35. "High grade prostatic intraepithelial neoplasia with adjacent small atypical glands (PINATYP) on core needle biopsy: A clinicopathologic analysis of 54 cases with emphasis on predictors of prostate cancer". Poster presentation. The United States and Canadian Academy of Pathology Meeting, Seattle, WA, 2016.
36. "Atypical Intraductal Proliferation and Intraductal carcinoma of the prostate on core needle biopsy: A comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of Intraductal carcinoma". Poster presentation, The United States and Canadian Academy of Pathology, March 6, 2017, San Antonio, Texas.
37. "Morphologic Correlates of PTEN Loss in Prostate Cancer". Poster presentation, The United States and Canadian Academy of Pathology, March 21, 2018, Vancouver, Canada.

Non-peer reviewed scientific or medical publications/materials in print or other media

1.	**Shah RB**, Rubin MA. Applications of TMA technology. 12, Advance Laboratory, September 2002
2.	**Shah RB**, Betz B. Bladder Cancer Detection by Fluorescence In Situ Hybridization (FISH). MLabs Spectrum, 2008; 22(3).
3.	**Shah RB**. Changing definition of the Gleason grading of prostate cancer: An Update on current concepts and contemporary approach. Editorial. Pathology and Laboratory Medicine, Official publication of Gujarat Association of Pathologists and Microbiologists 2010 2(1):7-28.
4.	**Shah RB**. Translocation Carcinomas of the Kidney: An Expanding Clinical, Pathological, and Genetic Spectrum. Pathology and Laboratory Medicine, Official publication of Gujarat Association of Pathologists and Microbiologists. 2012; 4(1):7-11.
5.	**Shah RB**. Emerging Molecular Markers of Diagnosis and Prognosis in Prostate Cancer. Pathology and Laboratory Medicine, Official publication of Gujarat Association of Pathologists and Microbiologists 2013; 5 (1):5-18.